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Abstract 
 
Robert A. Campbell:  The Role of Different Cell Types on Thrombin Generation and Fibrin 
Clot Formation and Structure 
(Under the direction of Dr. Alisa S. Wolberg) 
 Previous studies have demonstrated that fibrin clot quality is dictated by the 
concentration of thrombin at the time of gelation.  These studies were conducted by adding a 
single concentration of thrombin to a solution of fibrinogen; however, in vivo, thrombin 
generation proceeds on a cell surface, where the concentration of thrombin changes during 
the reaction.  Surprisingly, few studies have examined how thrombin generation on a cell 
surface influences clot formation, structure, and stability.  The present work is a study of the 
cellular properties that influence thrombin generation and the ways in which these properties 
contribute to clot formation and stability. 
 Patients with hemophilia form clots that have increased fibrinolytic susceptibility due to 
reduced rates of thrombin generation.  With the goal of improving the rate of thrombin 
generation in these patients, we explored whether the combination of rehydrated, lyophilized 
(RL) platelets (a cellular component) and recombinant factor VIIa (rFVIIa, a drug used to 
treat hemophilia) improved thrombin generation and the quality of the fibrin network over 
rFVIIa alone.  Using an in vitro model of coagulation, we determined that RL platelets 
combined with 10 nM rFVIIa improved thrombin generation and clot stability to levels seen 
with 50 nM of rFVIIa alone.  We further determined that the mechanism responsible for this 
improvement involved the procoagulant nature of RL platelets, suggesting cellular 
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procoagulant activity can play a significant role in thrombin generation and the quality of the 
fibrin network. 
 We next focused on the role of vascular cells in thrombin generation and demonstrated 
that intravascular endothelial cells support low levels of thrombin generation, which results 
in the formation of a loose network of fibrin.  However, extravascular cells (fibroblasts and 
smooth muscle cells), support significantly higher rates of thrombin generation, which 
produce tighter fibrin networks.  Modulation of the endothelial cell procoagulant phenotype 
through cytokine stimulation caused thrombin generation and clot quality to shift to that 
observed for extravascular cells, suggesting a novel link between inflammation and 
thrombosis. 
 These studies provide a better understanding of the mechanisms through which thrombin 
generation on a cell surface ultimately affects the quality of the fibrin clot.  These findings 
will likely enhance our ability to design therapeutics for bleeding and thrombotic disorders. 
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Chapter 1 
Introduction: Thrombin Generation, Fibrin Clot Formation, and Hemostasis 
This chapter is based on and reproduced in part with permission from: 
Wolberg A.S.; Campbell, R.A. "Thrombin Generation, Fibrin Clot Formation and 
Hemostasis" Transfus Apher Sci. 2008, 38(1), 15-23. 
 
1.1 Abstract 
 Hemostatic clot formation entails thrombin-mediated cleavage of fibrinogen to fibrin.  
Previous in vitro studies have shown that the thrombin concentration present during clot 
formation dictates the ultimate fibrin structure.  In most prior studies of fibrin structure, 
clotting was initiated by adding thrombin to a solution of fibrinogen; however, clot formation 
in vivo occurs in an environment in which the concentration of free thrombin changes over 
the reaction course.  These changes depend on local cellular properties and available 
concentrations of pro- and anti-coagulants.  Recent studies suggest that abnormal thrombin 
generation patterns produce abnormally structured clots associated with an increased risk of 
bleeding or thrombosis.  Further studies of fibrin formation during in situ thrombin 
generation are needed to understand fibrin clot formation in vivo. 
1.2 Fibrinogen and fibrin clot formation. 
 Fibrinogen is a 450 Å, 340 kDa trinodular protein present at high (2 – 4 mg/mL) 
concentrations in plasma.  Fibrinogen consists of pairs of three different disulfide-linked 
polypeptide chains:  A?, B?, and ?.  These six polypeptide chains are arranged with their N-
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termini converged in a central “E” domain of the molecule.  The C-termini of the B? and 
? chains extend outward into distal “D” domains.  The C-termini of the A? chains are 
globular and situated near the central E domain of fibrinogen where they interact intra-
molecularly (Figure 1.1) [3].  Comprehensive reviews on the biochemistry of fibrinogen and 
fibrin structure have been published [4-6]. 
 Mechanisms of fibrin production have been elucidated in studies conducted by adding 
exogenous thrombin to purified fibrinogen.  These studies have shown that thrombin 
removes N-terminal peptides from the fibrinogen A? and B? chains, causing the spontaneous 
formation of half-staggered, double-stranded protofibrils followed by thickening of 
protofibril chains [7].  Initial formation of protofibrils occurs during a “lag” phase in which 
no increase in turbidity is detected.  Subsequent lateral aggregation of fibrin protofibrils 
causes an increase in turbidity.  The magnitude of the turbidity increase relates to the 
structure of the formed clot; formation of thicker fibers causes a greater increase in final 
turbidity [8, 9].  Fibrin formation can be followed spectrophotometrically [10, 11]; while, 
fibrin structure can be determined using electron or confocal microscopy [12-17]. 
1.3 The thrombin concentration influences fibrin clot formation, structure, and 
stability. 
 Fibrin clot structure depends on a number of variables, including pH, ionic strength, and 
concentrations of calcium, fibrinogen, and thrombin present during gelation [7, 10, 12, 18-
23].  In particular, the thrombin concentration influences both the fiber thickness and density 
of the fibrin clot.  Low thrombin concentrations produce very turbid, highly permeable fibrin 
clots that are composed of thick, loosely-woven fibrin strands (Figure 1.2).  Higher thrombin  
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Figure 1.1.  The structure of fibrinogen. A). A pictorial representation of a fibrinogen 
molecule showing the distal D regions and the central E region connected by the coiled-coil 
(adapted from [1]). Chains are color-coded with the A?-chain in blue, B?-chain in green, and 
the ?-chain in red.  B) A transmission electron micrograph of the fibrinogen molecule 
showing the trinodular structure. Individual fibrinogen molecules are indicated by red arrows 
[2]. 
A. 
B. 
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Figure 1.2.  The thrombin concentration present at the time of gelation dictates the 
fibrin clot structure.  Scanning electron (A an B) and laser confocal (C and D) micrographs 
of fibrin clots formed by adding thrombin [2.5 nM (A and C), or 10 nM (B and D)] to 
purified fibrinogen (1 mg/mL) in 20 mM HEPES (pH 7.4), 150 mM NaCl.  Scanning 
electron micrographs are at 76,030 X (micron bar is 200 nm).  Laser confocal micrographs 
are at 63 X (micron bar is 10 ?m). 
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concentrations produce relatively non-turbid, less permeable clots that are composed of a 
dense network of relatively thin fibrin strands (Figure 1.2) [13, 23-25].  The differential 
structures of these clots has been shown to impart varying degrees of stability (viscoelastic 
properties and resistance to fibrinolysis) on the clot.   
 Individual fibers have significant extensibility and elasticity [26, 27]; however, the 
potential influence of fiber thickness on the properties of individual fibers is not yet known.  
In contrast, the influence of clot structure on viscoelastic properties has been extensively 
examined.  These studies have shown the relationship between fibrin structure and clot 
stiffness to be highly complex, depending on fiber thickness, length, density, and degree of 
branching, and extent of cross-linking (reviewed in [23, 28]).  Generally, increased thrombin  
concentrations are associated with the formation of stiffer clots [29]; however, Ryan et al. 
observed that clots formed in the presence of thrombin concentrations above 0.25 U/mL 
(composed of thin fibers) are less stiff (smaller G’) compared to clots formed with lower 
thrombin concentrations (thicker fibrin fibers) [23].  The differences in findings from these 
studies may relate to differences in the experimental conditions (fibrinogen, thrombin and 
calcium concentrations, ionic strength, and pH). 
 Because fibrin functions as both a cofactor and a substrate for the fibrinolytic enzyme 
plasmin, the fibrin structure influences the clot’s susceptibility to fibrinolysis [14, 30-32].  
Compared to thick fibers, thin fibrin fibers support a slower rate of tPA-mediated plasmin 
generation, reducing the rate of fibrinolysis [33].  An elegant study by Collet et al. (2000) 
showed that while thin fibers are lysed more quickly than thick fibers, clots composed of thin 
fibers are more resistant to fibrinolysis than clots composed of thick fibrin fibers [14].  These 
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studies indicate that clots formed in even “simple” purified systems with single thrombin 
concentrations exhibit complex functionality. 
1.4 Normal thrombin generation in situ. 
 In vivo, thrombin generation is an intricate and highly dynamic process.  Coagulation 
involves specific interactions between cellular surfaces and plasma-derived zymogens and 
cofactors.  The reactions are typically described in three sequential phases: (i) initiation, (ii) 
amplification, and (iii) propagation.  During the initiation phase, active tissue factor is 
exposed to plasma, permitting formation of a complex between factor VIIa and tissue factor.  
The factor VIIa/tissue factor complex activates factors IX and X.  During the amplification 
phase, the factor VIIa/tissue factor-activated factor Xa promotes small-scale thrombin 
generation, which activates cofactors VIII, V and platelets.  Phosphatidylserine exposed on 
activated platelets provides binding sites for procoagulant zymogens and enzymes, including 
factors IXa, VIIIa, X, Xa, Va, and II [34-37].  During the propagation phase, intrinsic 
activities supported by the activated platelet surface, produce a large-scale thrombin burst 
that catalyzes the conversion of fibrinogen to fibrin (Figure 1.3) [38, 39].  Thrombin 
produced during these phases also activates the transglutaminase factor XIII, which catalyzes 
formation of covalent bonds between ??chains and between ?? and A?? chains [40].  Cross-
linking increases the elasticity of individual fibers in the clot [26], as well as the overall 
viscoelasticity of the fibrin clot [18].  Ultimately, fibrin promotes the generation of plasmin 
to degrade the clot, and re-establish a blood supply for new cells proliferating at the site.  
 During a coagulation reaction, the concentration of free thrombin present can range from 
less than 1 nM to greater than 500 nM.  When thrombin generation is followed using 
chromogenic or fluorogenic substrates, a characteristic pattern emerges [42-45].  This pattern  
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Figure 1.3.  Conceptual model of cellular tissue factor (TF)-initiated in situ thrombin 
generation.  Coagulation is thought to occur in sequential phases, including initiation, 
propagation, and amplification. Initiation begins with the exposure of TF to plasma, 
formation of a factor VIIa/TF complex, and activation of factors IX and X. Propagation 
involves extrinsic activities whereby the factor VIIa/TF-activated factor Xa participates in 
small-scale thrombin generation on the TF-bearing cell, which activates factors VIII and V 
and platelets.  The initial burst of thrombin results in the activation of platelets that have 
exposed PS and specific binding sites for procoagulant enzymes and zymogens, including 
factors IXa, VIIIa, X, Xa, Va, and II.  Amplification proceeds via intrinsic activities on the 
surface of the activated platelet, resulting in a thrombin burst.  This thrombin then goes on to 
cleave fibrinogen to form the fibrin clot [39]. 
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correlates with the phases of coagulation described above.  The small amounts of thrombin 
produced during the initiation/amplification phases are not detectable in amidolytic assays 
(lower limit of detection ~1 nM), resulting in a lag phase in the thrombin generation profile 
(Figure 1.4).  The large burst of thrombin generation that occurs in the propagation phase on 
the activated platelet surface produces a maximum rate of increase in detectable free 
thrombin (Figure 1.4).  When the rates of thrombin production and thrombin inhibition reach 
equilibrium, the thrombin generation profile exhibits a peak (Figure 1.4).  Finally, the drop in 
thrombin production allows the amount of free thrombin to decrease, which is seen as a 
return to baseline in the thrombin generation profile (Figure 1.4).  The total amount of free 
thrombin measured during the reaction course is referred to as the area under the curve 
(AUC) or endogenous thrombin potential (ETP) (Figure 1.4).  
 The turbidimetric pattern of fibrin clot formation during in situ thrombin generation 
resembles the pattern seen after exogenous thrombin is added to purified fibrinogen (Figure 
1.4).  A lag phase, followed by a rapid increase in turbidity indicates clot formation in both 
situations.  However, the “lag” phase of clot formation during in situ thrombin generation is 
more complex, reflecting not only protofibril formation, but also the time required to 
generate thrombin on the tissue factor-bearing cell surface, activate cofactors and platelets, 
and commence thrombin generation on the surface of activated platelets.  
 The biochemical environment required for in situ thrombin generation can profoundly 
affect fibrin formation.  Assembly of procoagulant complexes and generation of thrombin 
requires calcium, which shortens the onset of clotting and produces thicker fibrin fibers than 
are seen in the absence of calcium [20].  Additionally, several plasma proteins can directly or 
indirectly affect thrombin activity and fibrin formation.  Antithrombin inhibits free thrombin,  
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Figure 1.4.  During in situ thrombin generation, fibrin clot formation occurs in an 
environment of dynamically changing thrombin concentrations. Thrombin generation 
can be described in phases: lag (A1), maximum rate (A2), peak (A3) and total free thrombin 
produced (area under the curve, A4). Fibrin clot formation occurs concurrent with thrombin 
generation. In contrast to exogenous thrombin addition, the lag phase in the clot formation 
turbidity curve (B1) is a complex function reflecting initial thrombin generation on the TF-
bearing cell, platelet activation (which produces an initial decrease in turbidity), thrombin 
generation on platelets, and protofibril formation. Lateral aggregation (B2) occurs during the 
thrombin burst phase when the thrombin concentration is increasing. Adapted from [39].    
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effectively lowering the apparent thrombin concentration, and resulting in prolonged times to 
gelation and thicker fibrin fibers [46-50].  Albumin, ?-globulin, and hemoglobin shorten the 
onset of fibrin clot formation, a phenomenon hypothesized to be caused by their influence on 
macromolecular interactions in the clotting solution [48, 51].  Further, these proteins cause 
significant differences between magnetic birefringence curves of fibrin polymerization in 
recalcified plasma and those of pure fibrinogen and thrombin solutions [48].  Cells can 
influence local fibrin structure via direct interactions between integrins and fibrin(ogen).  
Cellular integrins organize fibrin into tighter bundles near the cell surface than are seen more 
distally within the clot.  Furthermore, cell-associated fibrin is more resistant to fibrinolysis 
than distally-located fibrin [52-54].  Cells also release intracellular stores of soluble proteins 
that influence clot formation and stability, including factor XIII, plasminogen activator 
inhibitor-1 (PAI-1), and fibrinogen [52, 55-58]. 
1.5 Effect of the thrombin generation pattern and location on fibrin clot formation and 
structure. 
 Differences in cellular procoagulant activity and plasma factor levels can alter the relative 
influences of extrinsic and intrinsic activities during coagulation [15, 16, 44, 59-64].  
Variations in these activities produce different patterns of thrombin generation, causing 
variations in the concentration of thrombin present during protofibril and fiber formation.  
Fibrinopeptide release may occur under low, medium, or high thrombin concentrations, 
resulting in significantly different kinetics of fibrinopeptide release and fibrin polymerization 
compared to assays in which a single thrombin concentration catalyzes the release of all 
fibrinopeptides.  Since fibrinopeptide release dictates protofibril formation and lateral 
aggregation, clots produced during in situ thrombin generation contain considerably 
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heterogeneous fibrin structures [15, 16, 48, 65, 66].  Thus, the composition of a given clot 
may be quite specific to the circumstances under which it formed. Additionally, following 
formation of the initial clot, fibrin-bound thrombin released during clot lysis can modulate 
subsequent platelet procoagulant activity and fibrin deposition [67-69]. 
 It is currently hypothesized that extrinsic activities (on the TF-bearing cell) and intrinsic 
activities (on the surface of activated platelets) play specific, independent roles during 
different stages of thrombin generation and fibrin formation [70-73].  Low thrombin 
concentrations (less than 1 nM) are sufficient to trigger the onset of fibrin formation, and can 
be rapidly produced via extrinsic activities on surface of tissue factor-bearing cells.  Thus, the 
onset of clot formation depends on the nature and procoagulant properties of the tissue 
factor-bearing cells.  Since different tissue factor-bearing cells support different levels of 
procoagulant activity, they differ in their ability to initiate fibrin formation [71, 74-76].  
Interestingly, Ovanesov et al. (2005) showed that the rate of thrombin generation on  tissue 
factor-bearing cells does not influence the rate of propagation of fibrin into the plasma milieu 
[71].  Rather, propagation of fibrin away from the site of initiation depends on the plasma 
composition and procoagulant activity of the surrounding milieu [71].  These findings 
suggest that thrombin generated on the surface of platelets during the propagation phase 
dictates that rate of fibrin clot formation away from the initiating cells [70-73]. 
 Fibrin formation during cell-mediated thrombin generation likely includes a complex 
spatial component as well.  It is likely that this physical progression of procoagulant activity 
from the tissue factor-bearing cell (low levels of thrombin generation) to the activated 
platelet surface (rapid burst of thrombin generation) induces the formation of a thrombin 
gradient in space.  Given the direct effects of thrombin concentration on fibrin formation, this 
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gradient may therefore, cause the formation of a range of fiber thicknesses across a region of 
growing thrombus. 
1.6 Pathologic effects of altered thrombin generation on fibrin clot formation, structure, 
and stability.   
 Many studies have shown that the fibrin structure strongly influences the mechanical and 
fibrinolytic stability of the clot.  Current thinking suggests that these differences in stability 
have significant physiologic implications.  Dense, highly stable clots are associated with 
thrombosis; while, loosely-woven, unstable clots are associated with bleeding disorders [14, 
30-32, 77-81].  We and others have correlated abnormal patterns of thrombin generation with 
the formation of abnormal fibrin clots.  We hypothesize that the altered thrombin generation 
pattern contributes to thrombotic or bleeding complications via its influence on fibrin 
structure and stability. 
 Hyperprothrombinemia – The G20210A mutation in the 3’ untranslated region of 
prothrombin causes increased plasma levels of prothrombin.  Several studies have identified 
an increased risk of venous thrombosis in individuals with this mutation [82-84].  In in vitro 
assays, elevated prothrombin levels increase the maximal rate, peak and area under the curve 
of thrombin generation [15, 44, 62, 85].  We have shown that elevated (pro)thrombin levels 
trigger the formation of densely-packed fibrin clots composed of thin fibrin fibers compared 
to normal clots (Figure 1.5) [15].  Increased thrombin generation in these individuals also 
increases activation of the thrombin-activatable fibrinolysis inhibitor (TAFI) in vitro [86].  
Activated TAFI downregulates fibrinolysis by cleaving C-terminal lysine residues from 
fibrin and reducing the number of tPA and plasminogen binding sites on fibrin.  It has been 
suggested that the combination of abnormal structure and increased TAFI activation reduces  
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Figure 1.5.  Elevated levels of prothrombin increase the rate of thrombin generation 
and produce clots with thinner fibers.  A) Reactions were performed as we have described. 
As the concentration of prothrombin increases, the rate of thrombin generation increases.  B). 
Transmission electron micrograph (TEM) and scanning electron micrograph (SEM) of fibrin 
gel network from clots formed in the presence of 100% and 300% plasma prothrombin 
levels.  Original magnification ? 10 000; bar 0.5 ?m (TEM). Adapted from [13]. 
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the rate of fibrinolysis and contributes to the increased risk of thrombosis in these 
individuals. 
 Hemophilia and recombinant factor VIIa – The bleeding disorders hemophilia A or B 
result from deficiency in factors VIII or IX activities, respectively.  Hemophilic plasma 
exhibits relatively normal extrinsic (initiating) activities on tissue factor-bearing cells, but 
reduced intrinsic (propagating) activities on platelets.  Skin biopsies of wounds in hemophilic 
patients show a thin peripheral layer of fibrin deposited around a central region containing 
relatively few fibrin fibers [87].  These findings are consistent with normal, low level 
thrombin and fibrin generation on and near tissue factor-bearing cells at the periphery of the 
wound, but deficient thrombin propagation and fibrin formation into the central region of the 
wound.  In vitro assays modeling hemophilic conditions demonstrate delayed onset of 
measurable thrombin generation, as well as a reduced maximum rate and peak of thrombin 
generation [16, 44, 45, 88].  These reduced rates and levels of thrombin generation decrease 
the rate of fibrinopeptide release and delay fibrin formation (Figure 1.6) [88-90].  
Additionally, in vitro assays indicate that hemophilic clots are composed of abnormally thick 
fibrin fibers and have increased porosity compared to normal clots (Figure 1.6) [16, 91, 92].  
The fiber composition of hemophilic clots decreases their mechanical stability and makes 
them highly susceptible to fibrinolysis [16, 93, 94].  In vitro studies suggest that reduced 
thrombin levels limit TAFI activation, leaving clots more vulnerable to fibrinolysis [93, 95, 
96].  The physiologic importance of TAFI in clot stability is unclear, however, since TAFI-
deficient animals exhibit minimal to no bleeding [97-99]. 
 Recombinant factor VIIa (rFVIIa, NovoSeven) is approved for the treatment of severe 
bleeds in hemophilic patients with inhibitory antibodies, and has demonstrated efficacy under  
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Figure 1.6.  The absence of factors VIII and IX reduces the rate of thrombin generation 
and produces clots with thicker fibers.  A) In the absence of factors VIII and IX, the onset 
and rate of thrombin generation is reduced.  B) Scanning electron micrographs show fibrin 
clots formed in the presence (normal) and absence (hemophilia) of factor IX.  Original 
magnification 21900 x; bar 1 ?m. Adapted from [14]. 
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these conditions and in patients with acquired hemophilia [100].  By binding to the surface of 
activated platelets, rFVIIa re-establishes platelet tenase activity and restores thrombin 
generation on the platelet surface [101].  RFVIIa increases the maximum thrombin 
generation rate and shortens the time to reach the peak thrombin level in hemophilic 
conditions [16].  In vitro assays of hemophilic plasma and whole blood have shown that 
rFVIIa activity shortens the onset of clot formation and enables the formation of clots with 
thinner, more normal fibrin fibers, significantly improving the clot structure, porosity, and 
stability [16, 90, 92, 94].  By increasing the rate of fibrin formation, rFVIIa improves fibrin 
clot formation during a fibrinolytic challenge [16].  RFVIIa may further protect the clot by 
increasing TAFI activation [96].  Recently, several “superactive” analogs of rFVIIa have 
been described and tested in vitro and in animal models.  These analogs demonstrate similar 
procoagulant and anti-fibrinolytic properties as rFVIIa, but at significantly lower 
concentrations [94, 102, 103]. 
1.7  Focus of this dissertation 
 Multiple studies have used artificial conditions to demonstrate that local pH, ionic 
strength, and the concentrations of calcium, fibrinogen, and thrombin can influence clot 
structure and stability (reviewed in [39]).  However, the concentration of thrombin present at 
the time of gelation is likely to have the most profound physiologic influence on clotting.  In 
vivo, thrombin is actively generated on a cell surface, resulting in an ever-changing thrombin 
concentration.  Therefore, to fully appreciate the role of thrombin in determining clot 
structure, it is important not to study only a single concentration of thrombin, but to examine 
how modulating the rate of thrombin generation on a cell surface influences fibrin clot 
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structure.  Surprisingly few studies have examined how different vascular cells influence clot 
formation, structure, and fibrinolytic stability.   
 Furthermore, patients with systemic hypercoagulability develop thrombi in specific and 
characteristic locations in the vasculature (reviewed in [64, 100]).  To explain these regional 
differences in thrombus formation, it has been proposed that the local cell population 
contributes to localized thrombus formation [64, 104], which further emphasizes the 
importance of considering the local cell population.  Therefore, the overall objective of this 
dissertation was to determine the properties of vascular cells that dictate in situ 
thrombin generation and examine how these properties influence the spatial 
characteristics of clot architecture and lysis.  By understanding the connections between 
cellular properties and clot structure, it will be possible to develop future therapies that are 
safe and effective in preventing bleeding and arterial and venous thrombosis. 
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Rehydrated, Lyophilized Platelets Increase rFVIIa-mediated  
Thrombin Generation and Clot Formation and Stability 
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2.1  Abstract 
 Recombinant factor VIIa (NovoSeven, rFVIIa) is used to abrogate bleeding in 
hemophiliacs with inhibitors and is hypothesized to work by increasing factor Xa generation 
on the platelet surface.  We hypothesize that rFVIIa activity can be increased by the co-
addition of platelet procoagulant surface.  In this study, we have characterized the ability of a 
rehydrated, lyophilized (RL) platelet preparation to increase rFVIIa activity in hemophilic 
conditions.  RL platelets supported thrombin generation in the presence of factors VIII and 
IX, but in the absence of factors VIII and IX, thrombin generation was significantly reduced.  
RL platelets supported rFVIIa-mediated thrombin generation in a rFVIIa-concentration 
dependent manner.  In a cell-based in vitro model of hemophilia, the presence of RL platelets 
increased the rFVIIa-dependent thrombin generation rate up to 2.8-fold higher than rFVIIa, 
alone.  Similarly, the addition of RL platelets plus rFVIIa to the in vitro model of hemophilia 
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and to hemophilic platelet-rich plasma shortened the onset of clot formation and increased 
the stability in a fibrinolytic environment versus rFVIIa alone.  These results suggest that RL 
platelets can support rFVIIa-mediated thrombin generation, and that co-administration of RL 
platelets with rFVIIa may increase the efficacy of rFVIIa in some patients.   
2.2  Introduction 
 Deficiency of factor VIII or IX activities results in the bleeding diatheses hemophilia A 
or B, respectively.  Biochemically, hemophilia causes a deficiency in platelet tenase activity 
and, therefore, a lack of thrombin generation on the platelet surface [1].  In most patients 
with hemophilia, control of bleeding can be achieved through factor administration.  
However, in approximately 20 - 25% of patients with hemophilia, exposure to exogenous 
factor during therapy leads to the production of inhibitory antibodies directed against the 
replacement protein [2].  These inhibitory antibodies render the replacement therapy 
ineffective, necessitating the use of alternate therapeutic strategies and agents.  
 One agent developed for the treatment of severe bleeds in patients with hemophilia and 
inhibitors is recombinant factor VIIa (rFVIIa, NovoSeven; Novo Nordisk A/S, Copenhagen, 
Denmark) [3].  RFVIIa binds to the platelet surface in a phosphatidylserine- and calcium-
dependent manner, increasing factor Xa and thrombin generation on the platelet [4].  High 
plasma concentrations of rFVIIa are required for efficacy, reflecting the short half-life of the 
molecule [5], as well as the weak affinity of rFVIIa for the platelet surface (~90 nM) [4].  
Therefore, a therapy that permits pre-association of rFVIIa with platelets prior to 
administration may be of value. 
 Concerns about storage lesion [6] and microbial contamination [7] potentially limit the 
use of freshly-isolated platelets for this application.  However, several platelet substitutes are 
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currently being considered for novel therapeutics.  One recently described process involving 
treatment of platelets with paraformaldehyde permits platelets to be frozen and lyophilized 
while retaining their hemostatic capabilities.  This process results in the formation of 
rehydrated, lyophilized (RL) platelets, which are sterile and stable for long-term storage [8].  
RL platelets retain a near normal ultrastructure and express many functions of fresh platelets 
[8-10].  For example, RL platelets express glycoproteins IIbIIIa and IbIX that bind fibrinogen 
and von Willebrand factor, respectively [10].   Furthermore, RL platelets have been shown to 
effectively co-operate with endogenous coagulation mechanisms at the wound site to rapidly 
participate in hemostasis and reduce surgical bleeding in several animal models [8, 11-13].  
RL platelets have never been examined under hemophilic conditions or in conjunction with 
other hemostatic agents.   
 In this study, we examined the activity of rFVIIa on RL platelets.  Our results suggest 
that RL platelets support rFVIIa-mediated thrombin generation under hemophilic conditions.  
RL platelets combined with rFVIIa supported higher thrombin generation rates, shortened the 
onset time of clot formation, and improved fibrin clot formation in a fibrinolytic environment 
compared to rFVIIa, alone.  These results suggest that rFVIIa co-administered with RL 
platelets may increase the activity of rFVIIa. 
2.3  Experimental section 
Subjects 
 Blood was drawn with fully informed consent under a protocol approved by the 
University of North Carolina Institutional Review Board and General Clinical Research 
Center from donors who had not taken aspirin within two weeks of the blood draw or any 
other medication that could affect platelet activity within 72 hours of the blood draw. 
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Proteins and materials 
 Macrophage serum-free medium was purchased from Gibco (Grand Island, NY, USA).  
Chromozym Th (tosyl-gly-pro-arg-pNA), a chromogenic substrate for thrombin, was 
purchased from Boehringer-Mannheim (Indianapolis, IN, USA).  Prostaglandin E1, calcium 
ionophore, and lipopolysaccharide (Serotype 0128:B12, LPS) were purchased from Sigma 
(St. Louis, MO, USA).  SFLLRN was purchased from SynPep (Dublin, CA, USA).   
 Antithrombin III (ATIII) and factors VIII, IX and prothrombin were generously provided 
by Dr. Dougald M. Monroe (Department of Medicine, University of North Carolina at 
Chapel Hill).  ATIII, factor VIII, factor X, factor IX, and prothrombin were prepared as 
described [14].  Thrombin, plasmin, and factors V, Va, IXa, Xa, and XI were purchased from 
Haematologic Technologies Inc. (Essex Junction, VT, USA).  Factor X and plasminogen- 
and fibronectin-free fibrinogen were purchased from Enzyme Research Laboratories (South 
Bend, IN, USA).  Factor VIIa was the generous gift of Dr. Ulla Hedner (Novo Nordisk).  
Tissue factor pathway inhibitor (TFPI) was the generous gift of Dr. Jen-Yea Chang 
(Department of Medicine, University of North Carolina at Chapel Hill).  Tissue plasminogen 
activator (tPA) was purchased from American Diagnostica (Stamford, CT, USA).   The anti-
tissue factor antibody was generously provided by Dr. Steve Carson (University of Nebraska 
at Omaha) [15].  Annexin V was generously provided by Dr. Tze-Chein Wun (Evas 
Therapeutics, LLC).  Convulxin was generously provided by Dr. Christine Kempton (Emory 
University).  Innovin was purchased from Dade International Inc. (Miami, FL, USA). 
Cell isolation 
 Monocytes were purified as described [16, 17].  Platelets were freshly isolated from 
individual donors by density gradient centrifugation and gel filtration as described [18].  RL 
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platelets were prepared as described [8, 10].  Dried RL platelets were rehydrated in water, 
centrifuged at 150 x g for 10 minutes to pellet the platelets, and re-suspended in Tyrodes 
buffer [15 mM N-2-hydroxyetheylpiperazine-N’-2-ethanesulfonic acid (HEPES), 0.33 mM 
NaH2PO4 pH 7.4, 138 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5.5 mM dextrose] containing 1 
mg/mL bovine serum albumin (BSA).  RL platelets were counted with a hemocytometer. 
Platelet procoagulant activity and phosphatidylserine exposure 
 Fresh and RL platelets (10,000/μL, final) were treated with thrombin (10 nM, final), 
thrombin plus convulxin (10 nM and 1.2 nM, final, respectively), or calcium ionophore (10 
μM, final) for ten minutes at 37o C in the presence of CaCl2 (3 mM, final).  
Phosphatidylserine exposure was assayed by stimulating fresh and RL platelets (500/μL, 
final) with SFLLRN (50 μg/mL, final) in the presence of CaCl2 (3 mM, final) for ten minutes 
at 37
o
C.  Activated and unactivated platelets were then incubated with indicated 
concentrations of annexin V for 5 minutes.  Buffer-treated platelets served as unactivated 
platelet controls.  In both of these assays, activated and unactivated platelets were then 
incubated with factor Xa (1 nM, final), factor Va (5 nM, final), and prothrombin (1.4 μM, 
final) and thrombin generation was measured by sub-sampling reaction supernatants into 
chromogenic substrate, as described below. 
 To examine the ability of fresh and RL platelets to support factor Xa generation, platelets 
were activated in the presence of factor V (20 nM, final), factor VIII (0.3 nM, final), and 
CaCl2 (3 mM, final) for ten minutes at 37
o 
C.  Activated platelets (10,000/μL, final) were 
then added to factor IXa (20 nM, final), factor X (135 nM, final), and prothrombin (1.4 μM, 
final).  Hemophilia was simulated by omitting factors VIII and IXa.  Factor VIIa was 
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included in reactions as indicated.  At timed intervals, thrombin generation was measured by 
sub-sampling reaction supernatants into chromogenic substrate. 
Thrombin generation and clot formation in a cell-based model of coagulation 
 The cell-based model of coagulation was performed as described [14, 17, 19].  Briefly, 
the assay includes tissue factor-bearing monocytes (5000 cells/well), freshly-isolated 
platelets (100,000/μL), pro- and anti-coagulant proteins and, in indicated reactions, RL 
platelets (10,000/μL).  In all assays, zymogens were incubated with their inhibitors overnight 
at 4
o 
C to inhibit any activated proteases contaminating the zymogen preparations.  To start 
the reactions, freshly-isolated, unactivated platelets and RL platelets were combined with the 
protein/inhibitor concentrate and cofactors and immediately added to tissue factor-bearing 
monocytes.  Final protein concentrations were:  prothrombin (1.4 μM), factor V (20 nM), 
factor VIII (0.3 nM), factor IX (70 nM), factor X (135 nM), factor XI (25 nM), ATIII (2.5 
μM), TFPI (3 nM), and factor VIIa (0.2 nM).  Hemophilia was simulated by omitting factors 
VIII and IX.  Reactions were performed simultaneously in parallel wells with or without 
fibrinogen (2 mg/mL, final).  Plasmin (60 nM, final) was included in some fibrinogen-
containing wells, as indicated.  
 Pre-activated fresh platelets (10,000/μL), or additional unactivated platelets (10,000/μL) 
were also included in some of the model system reactions.  Pre-activated platelets were 
prepared by incubating fresh platelets with thrombin (10 nM, final) for ten minutes at 37
o 
C.  
The thrombin was then quenched by the addition of ATIII (2.5 μM, final) prior to adding to 
the reaction.  The same amount of ATIII was also added to the unactivated and RL platelet 
reactions. 
Measurement of thrombin generation 
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 At timed intervals, 10 μL of reaction supernatant were removed and quenched with 90 μL 
of 20 mM HEPES (pH 7.4), 150 mM NaCl (HBS) containing 10 mM ethylenediamine 
tetraacetic acid (EDTA) and 1 mg/mL BSA.  Quenched reactions were then diluted 1:10 in 
HBS containing 1 mM EDTA and 0.5 mM Chromozym Th.  The rate of substrate cleavage 
(change in absorbance at 405 nm versus time) for each sample was measured using a kinetic 
microplate reader (SpectraMax 340PC and SOFTmax PRO software; Molecular Devices, 
Sunnyvale, CA, USA).   The rate of thrombin generation for each time point was defined as 
the slope of a line fitted to the maximum rate of increase during the reaction.  The activity of 
thrombin used to activate the platelets was subtracted out as background, based on the 
activity present in the zero time point. 
 In the cell-based model system,  10 μL samples of the reaction mixture were removed at 
time intervals after initiating coagulation and assayed for thrombin activity by addition to 90 
μL of a solution of 1 mM EDTA, 0.5 mM Chromozym Th, 20 mM HEPES (pH 7.4), and 150 
mM NaCl.  Cleavage of the synthetic substrate Chromozym Th was stopped by the addition 
of 50% acetic acid, and the absorbance at 405 nm was compared to a standard curve of 
thrombin. 
Clotting in platelet-rich plasma   
 Platelet-rich plasma (PRP) from individual hemophilic donors was made by centrifuging 
citrated blood treated with corn trypsin inhibitor (18.5 μg/mL, final) at 150 x g for 10 
minutes.  “Normal” was simulated by adding factor VIII or IX to hemophilia A or B PRP.  
RFVIIa and RL platelets were included as indicated.  Clotting reactions were initiated by 
adding Innovin (1:30000, final) to recalcified PRP (20 mM CaCl2, final) in the presence of 
tPA (1 μg/mL, final).  Final reaction volumes were 100 μL.  
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Characterization of fibrin clots by turbidity  
 Clot formation and lysis were detected by turbidity changes at 405 nm in a SpectraMax 
340PC plate reader.  The time to onset of clot formation is a function of the time to initiation 
of thrombin generation plus the time of protofibril formation, and was defined as the time to 
the inflection point prior to the turbidity increase during clot formation.  The maximum slope 
was defined as the slope of a line fitted to the maximum rate of turbidity increase during clot 
formation (“Vmax” in the Molecular Devices software) using 5 – 10 points to determine the 
line.  The clot’s final optical density reflects the structure of the fibrin fibers comprising the 
clot [20, 21].  For plasmin challenge assays and platelet-rich plasma experiments, area under 
the curve (AUC) values were calculated as the sum of the trapezoids formed by the data 
points, less a baseline established by the lowest measurement taken (Kaleidagraph 3.6.4, 
Synergy Software, http://www.synergy.com). 
Statistical analysis 
 A two-sample t-test was used to compare statistical differences between rFVIIa and RL 
platelet treatment alone, compared to rFVIIa plus RL platelets, when examining onset and 
rate of thrombin generation, onset and maximum slope of fibrin clot formation, and AUC.  P 
< 0.05 was considered to be statistically significant. 
2.4  Results 
 RL platelets are procoagulant and have exposed phosphatidylserine on their 
surface.  For RL platelets to enhance rFVIIa therapeutic activity, the product must be 
procoagulant and able to support rFVIIa activity.  We first investigated the procoagulant 
activity of RL platelets stimulated by different platelet agonists.  RL platelets were incubated 
with thrombin, thrombin plus convulxin, calcium ionophore, or HBS (unstimulated control), 
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and the ability of platelets to support thrombin generation was measured and compared to 
freshly-isolated platelets.  Thrombin-stimulated freshly-isolated platelets supported thrombin 
generation; while, unstimulated fresh platelets did not (Figure 2.1a).  Freshly-isolated 
platelets stimulated with thrombin plus convulxin, or calcium ionophore (A23187), supported 
higher thrombin generation rates than thrombin, alone, consistent with that reported by 
Alberio et al. [22].  In contrast, unstimulated RL platelets supported significant 
prothrombinase activity and treatment with thrombin, convulxin or A23187 did not further 
increase their activity.  RL platelet procoagulant activity was greater than that of thrombin-
stimulated fresh platelets, but not as high as thrombin- and convulxin-co-stimulated fresh 
platelets.  The relative activity of RL platelets varied from 1.5 to 10-fold higher than 
thrombin-stimulated freshly-isolated platelets, depending on the individual donor of the fresh 
platelets. 
 We then determined whether RL platelets express phosphatidylserine on their surface.  
Fresh and RL platelets were activated with SFLLRN and incubated with different 
concentrations of the phosphatidylserine binding protein annexin V.  Factors Xa, Va, and 
prothrombin were then added to the platelets and thrombin generation was measured.  In this 
experiment, as the concentration of annexin V increases, free phosphatidylserine on the RL 
platelet surface decreases, which limits prothrombinase activity.  RL platelets supported 
similar thrombin generation rates in the presence and absence of SFLLRN.  The presence of 
annexin V decreased the thrombin generation rate in an annexin V concentration-dependent 
manner in both SFLLRN-activated fresh platelets and RL platelets (Figure 2.1b).  This 
observation indicates that RL platelets have constitutively-exposed phosphatidylserine on 
their surface. 
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Figure 2.1.  RL platelets are in a maximally activated state and have exposed 
phosphatidylserine on their surface.   Freshly-isolated and RL platelets (10,000/μL, final) 
were activated with thrombin, thrombin plus convulxin, and calcium ionophore and thrombin 
generation was measured as described in Experimental section.  A) The maximum rate of 
substrate cleavage at ten minutes for both freshly-isolated and RL platelets.  Rate (± standard 
deviation) are shown in duplicate from one experiment, representative of three separate 
experiments.  B) Freshly-isolated platelets and RL platelets were treated with HBS or 50 
μg/mL SFLLRN.  Platelets (500/μL, final) were then incubated with different concentrations 
of annexin V.   Thrombin generation was measured as described in Experimental section.  
The maximum rate of substrate cleavage at 60 minutes is plotted for both freshly-isolated and 
RL platelets.  Rate (± standard deviation) are shown in duplicate from one experiment, 
representative of four separate experiments.  C) Tissue factor-bearing monocytes were 
incubated with unactivated platelets, catalytic amounts of factor VIIa, calcium, plasma 
concentrations of factors II, IX, X, V, VIII, ATIII, and TFPI and no additional platelets, or 
with the addition of 10,000/μL unactivated, activated, or RL platelets.  At the times shown, 
samples were removed and assayed for thrombin as described in Experimental section.  The 
data shown are from one experiment, representative of five separate experiments. 
BA
C
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 Given these findings that RL platelets resemble activated platelets with surface-exposed 
phosphatidylserine and procoagulant activity, we compared the activity of RL platelets to 
pre-activated fresh platelets in a cell-based model of normal coagulation [17, 23, 24].  Since 
our experiments suggested that RL platelets had as much as 10-fold higher activity than 
activated fresh platelets (Figures 2.1a, 2.1b, and data not shown), we included RL platelets at 
1/10
th
 the concentration of fresh platelets.   Thus, in these experiments, the initial 
concentration of fresh, unactivated platelets was 100,000 platelets/μL in all wells, and the 
effects of adding 10,000/μL RL platelets were compared to that of adding 10,000/μL fresh 
pre-activated platelets, or 10,000/μL fresh, unactivated platelets.  The addition of fresh, 
unactivated platelets had minimal effects on thrombin generation (Figure 2.1c).  The addition 
of fresh, pre-activated platelets caused an earlier onset of thrombin generation, likely due to 
the early exposure of both phosphatidylserine and platelet factor Va.  Fresh, pre-activated 
platelets did not change the rate of thrombin generation or peak level reached (Figure 2.1c).  
In contrast, the addition of RL platelets did not shorten the onset of thrombin generation or 
change the area under the curve, but produced a faster maximum rate and higher peak in a 
dose-dependent manner (Figure 2.1c and data not shown).   Together, these findings suggest 
that RL platelets express phosphatidylserine, do not express active factor Va (data not 
shown), but support a higher thrombin generation rate and peak than thrombin-activated 
fresh platelets. 
 RL platelets support rFVIIa-mediated thrombin generation in the absence of 
factors VIII and IX.  To determine whether RL platelets support rFVIIa activity, we 
incubated RL platelets with factors X, V, and II under normal conditions (presence of factors 
VIII and IXa), hemophilic conditions (absence of factors VIII and IXa), and hemophilic 
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conditions with rFVIIa.  Timed samples were assayed for thrombin by the rate of cleavage of 
a chromogenic substrate.  Thrombin generation under these conditions requires factor Xa 
generation prior to assembly of the prothrombinase complex.  As depicted in Figure 2.2a, 
thrombin generation on both freshly-isolated and RL platelets appears linear in the presence 
of factors IXa and VIIIa, reflecting the high rate of factor Xa generation by the preformed 
factor IXa/VIIIa complex.  In contrast, since rFVIIa-mediated factor Xa generation is 
relatively inefficient; thrombin generation was slower and exhibits a lag phase prior to 
measurable thrombin detection [4, 25]. 
 Like freshly-isolated platelets, RL platelets supported thrombin generation in the 
presence of factors VIII(a) and IXa; however, in the absence of factors VIII(a) and IXa, 
thrombin generation was significantly reduced (Figure 2.2a).  Also similar to freshly-isolated 
platelets, the addition of 50 nM rFVIIa increased, but did not fully normalize thrombin 
generation on RL platelets.  Because thrombin generation was not seen when factor X was 
excluded from the reaction (data not shown), these data suggest that rFVIIa increases 
thrombin generation in a factor X-dependent manner, by directly cleaving factor X on RL 
platelets.  For all conditions tested, RL platelets promoted thrombin generation rates around 
1.5 to 10-fold higher than freshly-isolated platelets, depending on the fresh platelet donor.   
 We then compared the rFVIIa concentration-dependent response of thrombin generation 
to rFVIIa concentration on fresh and RL platelets.  RL platelets were incubated with factors 
X, V, prothrombin, and concentrations of rFVIIa ranging from 1 - 250 nM, and thrombin 
generation was measured.  Like freshly-isolated platelets, thrombin generation on RL 
platelets was dose-dependent with respect to the rFVIIa concentration (Figure 2.2b).
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Figure 2.2.  RL platelets support thrombin generation.  A) Freshly-isolated platelets and 
RL platelets were activated as described in Materials and Methods.  Platelets were then 
incubated in the presence of factors VIII and IXa, in the absence of factors VIII and factor 
IXa, and in the absence of factors VIII and IXa with the addition of 50 nM rFVIIa.  
Following addition of factors X and prothrombin, thrombin generation was measured in 
timed samples using a chromogenic substrate as described in Experimental section.  The 
thrombin generation rates (± standard deviation) are shown in duplicate from one 
experiment, representative of three separate experiments.  B) Freshly-isolated (open 
diamonds) and RL platelets (closed diamonds) (10000 platelets/μL) were activated as 
described in Experimental section.  Platelets were then incubated with factor X and 
prothrombin, and with different concentrations of rFVIIa.  Aliquots were removed at timed 
intervals, quenched with EDTA, and thrombin production was measured with a chromogenic 
substrate.  The maximum rate of substrate cleavage at 30 minutes for both freshly-isolated 
and RL platelets were plotted to obtain a dose response curve.  Thrombin generation rate (± 
standard deviation) are shown in duplicate from one experiment, representative of three 
separate experiments. 
A B. 
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Concentrations of rFVIIa producing half-maximal thrombin generation were similar for 
freshly-isolated and RL platelets (120 ± 7.5 nM and 137 ± 43.4 nM, respectively).   
 To examine whether rFVIIa activity on RL platelets depended on the presence of platelet-
derived tissue factor, thrombin-activated RL platelets were pre-incubated with an inhibitory 
anti-tissue factor antibody (10 μg/mL, final) or HBS for five minutes at 37o C.  RL platelets 
were then added to rFVIIa, factor X, factor V, and prothrombin, and thrombin generation was 
measured.  Thrombin generation was slightly reduced in the reactions containing the anti-
tissue factor antibody (results not shown), but these differences were not significantly 
different. 
 RL platelets augment rFVIIa-mediated thrombin generation in a cell-based model 
of hemophilia.  Thrombin generation was followed in an in vitro, cell-based model of 
hemophilia [17, 19, 23, 24].  Consistent with earlier findings [4, 17, 19], the absence of 
factors VIII and IX (“hemophilia”) prolonged the onset of thrombin generation and reduced 
the maximum rate of thrombin generation  compared to normal conditions (presence of 
factors VIII and IX) (Figure 2.3).  We specifically examined the effects of two concentrations 
of rFVIIa: 10 nM rFVIIa is below the plasma level that would be achieved with therapeutic 
dosing; while, 50 nM rFVIIa is equivalent to a therapeutically recommended dose of 180 
μg/kg.  Similar to previous studies [4, 17, 19], both 10 nM and 50 nM rFVIIa shortened the 
onset time and increased the rate of thrombin generation in the absence of factors VIII and 
IX.  Neither concentration normalized the onset time, nor the rate of thrombin generation. 
 When RL platelets were added to hemophilic conditions in the presence of 50 nM rFVIIa, 
the onset time of thrombin generation was shortened compared to equivalent concentrations  
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Figure 2.3.  In a cell-based in vitro model of hemophilia, RL platelets plus rFVIIa 
increase the rate and peak of thrombin generation more than rFVIIa, alone.  Reactions 
to measure thrombin generation were performed in the cell-based model system as described 
in Experimental section.  Hemophilic reactions were performed in the presence or absence of 
rFVIIa (10 nM or 50 nM) and RL platelets (10,000/μL).  At the times shown, samples were 
removed and assayed for thrombin as described in Experimental section.  The data shown are 
from one experiment, representative of six separate experiments. 
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of rFVIIa (p<0.05) or RL platelets (p<0.05), alone (Figure 2.3).  Both concentrations of 
rFVIIa combined with RL platelets significantly increased the rate of thrombin generation 
versus rFVIIa (p<0.05) or RL platelets (p<0.05), alone.  The effect of 10 nM rFVIIa plus RL 
platelets on the thrombin generation rate was statistically indistinguishable from 50 nM 
rFVIIa, alone.  Interestingly, 50 nM rFVIIa plus RL platelets almost fully normalized the 
onset of thrombin generation.  When RL platelets, alone, were added to hemophilic 
conditions, there was minimal to no effect on the onset or rate of thrombin generation (Figure 
2.3), indicating that the procoagulant effects required the presence of both rFVIIa and RL 
platelets.  
 RL platelets improve rFVIIa-mediated clot formation in a cell-based model of 
hemophilia.  Clot formation was followed in the cell-based model of hemophilia by 
monitoring the turbidity increase of reactions performed in the presence of 2 mg/mL 
fibrinogen.  Consistent with previous studies, when compared to normal conditions (presence 
of factors VIII and IX), hemophilic conditions (omission of factors VIII and IX) prolonged 
the onset of clot formation and reduced the maximum rate of clot formation (Figures 2.4a –
2.4c) [17, 19].  The addition of 10 or 50 nM rFVIIa to hemophilic conditions shortened, but 
did not fully normalize the onset time of clot formation (Figures 2.4a and 2.4b).  Similar to 
earlier studies, the rate of clot formation did not significantly change with the addition of 10 
or 50 nM rFVIIa (Figures 2.4a and 2.4c) [17, 19].  
 Both concentrations (10 and 50 nM) of rFVIIa plus RL platelets significantly shortened 
the onset time of clot formation versus equal concentrations of rFVIIa (p<0.05) or RL 
platelets (p<0.05), alone under hemophilic conditions (Figures 2.4a and 2.4b).  Furthermore, 
both 10 and 50 nM rFVIIa plus RL platelets significantly increased the maximum rate of clot 
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Figure 2.4.  RL platelets plus rFVIIa shorten the onset and increase the rate of fibrin 
clot formation in an in vitro model of hemophilia more than rFVIIa, alone.  Reactions to 
measure clot formation were performed in the cell-based model system in the presence of 2 
mg/mL fibrinogen, as described in Experimental section.  Clot formation was monitored by 
an increase in turbidity.  A) Clot formation curves from a single experiment, representative of 
six separate experiments.  B) RFVIIa plus RL platelets shortened the onset time of clot 
formation over rFVIIa treatment alone. C) RFVIIa plus rFVIIa increased the rate of clot 
formation over rFVIIa treatment alone.  For panels B and C, the data (± standard error of the 
mean) are averaged from all six experiments performed.  
A B. 
C
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formation compared to equal concentrations of rFVIIa (p<0.05) or RL platelets (p<0.05), 
alone in the absence of factors VIII and IX (Figures 2.4a and 2.4c).  Interestingly, the 
addition of 10 nM rFVIIa plus RL platelets resulted in a similar clotting onset time as 50 nM 
rFVIIa, alone.  The onset time and maximum rate of clot formation of 50 nM rFVIIa plus RL 
platelets was statistically indistinguishable from normal (Figures 2.4a – 2.4c).  The addition 
of RL platelets, alone to hemophilic conditions had little to no effect on the onset time and 
maximum rate of clot formation.   
 RL platelets increase rFVIIa-mediated clot formation in a fibrinolytic environment. 
The plasmin challenge assay evaluates the ability of a fibrin clot to form in an existing 
fibrinolytic environment.  In this assay, plasmin is added to reactions prior to the initiation of 
clot formation.  Therefore, clot formation competes with clot lysis, which is indicated by an 
increase and subsequent decrease in turbidity [17, 19, 21].  At a given plasmin concentration, 
clot formation occurs as a function of the thrombin concentration.  Hemophilic conditions 
prevented the formation of a significant clot (Figures 2.5a and 2.5b) [17, 19].  In agreement 
with previous work [17, 19], the addition 10 nM or 50 nM rFVIIa improved, but did not 
normalize clot formation (Figures 2.5a and 2.5b).  The addition of RL platelets, alone, to 
hemophilic conditions had a minimal effect on clot formation and stability.  When added 
together to hemophilic conditions, both concentrations of rFVIIa plus RL platelets shortened 
the onset time, increased the rate of clot formation, and significantly improved stability 
(AUC) of the clot in fibrinolytic conditions versus when equivalent concentrations of rFVIIa 
(p<0.05) or RL platelets (p<0.05) was included, alone (Figures 2.5a and 2.5b).    
 RL platelets increase rFVIIa-mediated clot formation in platelet-rich plasma from 
hemophilia patients.  Finally, we examined the effect of RL platelets plus rFVIIa on clot  
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Figure 2.5.  In the presence of a plasmin challenge, RL platelets plus rFVIIa 
significantly improve hemophilic fibrin clot formation better than rFVIIa, alone.   
Reactions to measure clot formation in a fibrinolytic environment were performed in the cell-
based model system in the presence of 2 mg/ml fibrinogen and 60 nM plasmin, as described 
in Experimental section.  A) Clot formation (absorbance increase) and lysis (absorbance 
decrease) were followed at 405 nm.  The data shown are from one experiment, representative 
of four experiments.  B) Area under the curve measurements quantitating the effects of RL 
platelets and rFVIIa in the plasmin challenge assay.  Data (± standard error of the mean) 
shown are from an average of four separate experiments.   
A B. 
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formation and lysis in hemophilic PRP from three severe hemophilia A patients and one 
severe hemophilia B patient.  “Normal” was simulated by adding factors VIII or IX to 
hemophilia A or B PRP, respectively.  For all assays, hemophilic clot formation was  
significantly reduced or eliminated compared to “normal”, similar to our results in the 
plasmin challenge assays.  All hemophilic PRP samples demonstrated at least partially 
increased clot stability in the presence of rFVIIa.  The addition of RL platelets, alone, to 
hemophilic PRP had only a minimal effect on clot formation.    
 Upon addition of rFVIIa plus RL platelets to hemophilic PRP, our results fell into two 
categories:  1) those that had similar AUC when comparing rFVIIa/RL platelets versus 
rFVIIa, alone (one hemophilia A patient and one hemophilia B patient, Figures 2.6a and 
2.6b, respectively), and 2) those in which the AUC increased with the addition of rFVIIa/RL 
platelets versus rFVIIa, alone (two hemophilia A patients, Figures 2.6c and 2.6d).  
Interestingly, the two individuals who did not respond to the addition of RL platelets 
(category 1, no change in AUC +/- RL platelets) had already shown a significant response to 
the addition of rFVIIa, alone (Figures 2.6a and 2.6b); whereas, the two individuals with a 
strong response to RL platelets (category 2, significant increase in AUC with RL platelets 
versus without), had showed only a minimal response to addition of rFVIIa, alone (Figures 
2.6c and 2.6d).  One hemophilia A patient who was a rFVIIa/RL platelet responder was 
assayed on two separate days (separate blood donations) and demonstrated increased clotting 
in the presence of rFVIIa/RL platelets versus rFVIIa, alone, both times (data not shown). 
2.5  Discussion 
 The clinical efficacy of rFVIIa is believed to be limited in part by the weak affinity of 
rFVIIa to the platelet surface [4].  We hypothesize that a pre-formed rFVIIa/platelet complex  
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Figure 2.6.  RL platelets can augment rFVIIa-mediated procoagulant activity in 
hemophilic platelet-rich plasma.  Clot formation was initiated in PRP from three 
hemophilia A donors and one hemophilia B donor in the presence of tPA, as described in 
Experimental section.  “Normal” was simulated by adding factor VIII or factor IX to 
hemophilia A or B PRP, respectively.  Clot formation (absorbance increase) and lysis 
(absorbance decrease) were followed at 405 nm.  Two individuals exhibiting a strong 
response to rFVIIa, alone, but no further response to RL platelets are shown in Figures 2.6a 
and 2.6a (hemophilia A and B PRP respectively).  Two individuals exhibiting a weak 
response to rFVIIa, alone, but increased AUC to the addition of rFVIIa plus RL platelets are 
shown in Figures 2.6c and 2.6d (both hemophilia A PRP).  Reactions were normalized with 
the initial absorbance equal to zero. 
A B. 
DC
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could improve rFVIIa procoagulant activities in hemophilia.  In this study, we investigated 
the ability of a preserved platelet population (RL platelets) to support rFVIIa-mediated 
activity and increase thrombin generation and clot formation in hemophilic conditions in 
vitro.  Our results suggest RL platelets have exposed phosphatidylserine on their surface and 
can support procoagulant activity.  RFVIIa increased thrombin generation on RL platelets in 
a concentration-dependent manner, and rFVIIa plus RL platelets improved thrombin 
generation in a cell-based model of hemophilia versus rFVIIa, alone.  Importantly, our data 
in both the cell-based model and hemophilic PRP showed that rFVIIa plus RL platelets 
shortened the onset and increased the rate of clot formation and stability of the clot versus 
rFVIIa, alone.  The addition of RL platelets, alone, had little to no effect in our assays, 
suggesting that RL platelets do not carry or contribute factors VIII or IX to the reactions and 
thus do not act as vehicles carrying “replacement factor.”  Thus, our study supports the 
hypothesis that RL platelets would increase the activity of rFVIIa in hemophilic conditions. 
 Our data show that RL platelets constitutively express PS and support 1.5 to 10-fold 
higher thrombin generation rates than freshly-isolated platelets (Figures 2.1 and 2.2).  
Previous reports have demonstrated that paraformaldehyde treatment of platelets causes the 
expression of platelet activation markers and phosphatidylserine [26-28].  Since the protocol 
for making RL platelets includes a paraformaldehyde fixation step, it is likely that this step 
causes significant phosphatidylserine expression on RL platelets prior to thrombin 
stimulation.  High phosphatidylserine expression may promote the formation of increased 
prothrombinase complexes.  Indeed, rFVIIa-dependent thrombin generation in hemophilic 
plasma is significantly increased by phospholipids [29].  These results may explain the high 
procoagulant activity of RL versus fresh platelets, and why low concentrations of RL 
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platelets (1/10
th
 of the endogenous fresh platelet concentration) have significant effects on 
thrombin generation and clot formation in our in vitro assays (Figures 2.1c, 2.3, and 2.4).  
While RL platelets are strongly procoagulant in our in vitro assays, infusion of RL platelets 
into animals does not cause measurable activation of endogenous platelets or presentation of 
clinical symptoms of intravascular coagulation [13].  This apparent contradiction indicates 
that in vivo, RL platelets are regulated by negative feedback mechanisms or, due to their 
rapid clearance from the animal (minutes), are either directly targeted to the wound site to 
participate in hemostasis or removed from circulation before they cause intravascular 
coagulation [12]. 
 Our data suggest that RL platelets augmented rFVIIa activity in some hemophilic PRP 
experiments, but not in others.  The variability in response to RL platelets may be similar to 
that seen with rFVIIa, with patients characterized as “responders” or “non-responders” [30].  
Response to both rFVIIa and RL platelets may reflect the quality of the endogenous platelets 
in each individual.  That is, individuals with higher endogenous platelet procoagulant activity 
might be better able to support rFVIIa activity; while, those with lower endogenous platelet 
procoagulant activity could benefit from the addition of exogenous procoagulant surface.  
Support for this idea comes from Saxena et al (2006), who showed that hemophilia patients 
who had the ability to generate a higher percentage of coated-platelets after stimulation had 
fewer bleeds over a six month period compared to patients who generated a lower percentage 
of coated-platelets [31].  Therefore, individuals whose platelets are more responsive to 
rFVIIa may derive less “benefit” from the additional procoagulant activity provided by RL 
platelets.  In contrast, individuals whose platelets are less responsive to rFVIIa may 
  51 
demonstrate increased procoagulant activity in the presence of rFVIIa/RL platelets.  Further 
studies are ongoing to explore this relationship. 
 Our in vitro data provide a base for future in vivo studies to determine whether rFVIIa 
plus RL platelets can correct bleeding in hemophilic animals.   Several previous studies of 
RL platelets in vivo support the expectation that they will correct bleeding in these models [8, 
11-13].  In thrombocytopenic Sprague-Dawley rats, RL platelets shorten the toenail bleeding 
from greater than 15 minutes to less than 2 minutes [8].  RL platelets are successfully 
incorporated into bleeding time wounds of dogs with normal endogenous platelet 
concentrations, suggesting that the endogenous platelet population does not prevent RL 
platelets from binding to wounded endothelium [8].  RL platelets are approximately the same 
size as activated fresh platelets (data not shown).  Importantly, post-mortem examination 
demonstrates that while RL platelets localize to the wound site, they do not bind to healthy 
endothelium [11].  Thus, RL platelets react to shear, compete with the endogenous platelet 
population for incorporation into hemostatic plugs, participate in hemostasis, and behave as 
wound-targeting hemostatic agents in vivo.  Given our in vitro results and these previous 
findings from in vivo models, expectations are high that a rFVIIa/RL platelet therapeutic 
would be efficacious in animal models of bleeding. 
 The approach of combining rFVIIa with RL platelets or other platelet substitutes may 
have broader applications beyond hemophilia.  At high concentrations, rFVIIa can activate 
factor IX on the platelet surface, which may explain its ability to correct bleeding in non-
hemophilic individuals with traumatic bleeding and thrombocytopenia [32].  Based on our 
results, it is conceivable that rFVIIa would have similar factor IXa-generating activities on 
RL platelets, making a rFVIIa/RL platelet therapeutic approach useful for these situations as 
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well.  Furthermore, this study may spur future projects involving the use of other platelet 
substitutes in conjunction with rFVIIa or other coagulation proteins, including platelet-
derived microparticles and fibrinogen-coated albumin microcapsules (FAMs) [33, 34].   
Platelet-derived microparticles, which are microvesicles of platelet membranes formed 
during platelet activation or by mechanical disruption of the platelet membrane, possess 
similar hemostatic properties to fresh and RL platelets, including the expression of platelet-
specific proteins and phosphatidylserine [35, 36].   A previous study showed that when 
platelet membrane fragments combined with rFVIIa are perfused through denuded arterial 
segments, increased fibrin formation is observed over infusion of the fragments or rFVIIa 
alone [37].  Our study builds on these observations, suggesting that a therapy based on the 
co-infusion procoagulant surface with rFVIIa or other coagulation factors may be a 
promising approach.   
 In conclusion, we have shown that RL platelets support rFVIIa-mediated thrombin 
generation under hemophilic conditions and that RL platelets plus rFVIIa increase the 
thrombin generation rate over rFVIIa, alone.  We hypothesize that co-administration of 
rFVIIa and RL platelets would increase the activity of rFVIIa in hemophilia. 
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Chapter 3 
Cellular Procoagulant Activity Dictates Clot Structure and Stability 
This chapter is based on and reproduced in part with permission from: 
Campbell, R.A.; Overmyer, K.A.; Bagnell, C.R.; Wolberg, A.S. 
"Cellular Procoagulant Activity Dictates Clot Structure and Stability as a Function of 
Distance from the Cell Surface" Arterioscler Thromb Vasc Biol. 2008, 28(12), 2247–54. 
 
3.1  Abstract 
 Thrombin concentration modulates fibrin structure and fibrin structure modulates clot 
stability; however, the impact of localized, cell surface-driven in situ thrombin generation on 
fibrin structure and stability has not previously been evaluated.  Human fibroblasts were 
incubated with factors Xa, Va, prothrombin and fibrinogen, or plasma.  Fibrin formation, 
structure, and lysis were examined using laser scanning confocal microscopy and 
transmission electron microscopy.  In situ thrombin generation on the cell surface produced 
clots with a significantly denser fiber network in a 10-?m region proximal versus distal to 
(40 – 50 ?m) the cell surface.  This morphology was not altered by addition of integrin-
blocking RGDS peptide and was not apparent in clots made by exogenous thrombin addition, 
suggesting that spatial morphology was dictated predominantly by localized thrombin 
generation on the fibroblast surface.  The fibrin network lysed more rapidly distal versus 
proximal to the cell surface, suggesting that the clot's structural heterogeneity affected its 
fibrinolytic stability.  In situ thrombin generation on the cell surface modulates the three-
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dimensional structure and stability of the clot.  Thrombus formation in vivo may reflect the 
ability of the local cell population to support thrombin generation and therefore, the three-
dimensional structure and stability of the fibrin network.  
3.2  Introduction 
 Following vascular injury, thrombin-catalyzes the enzymatic conversion of soluble 
fibrinogen to an insoluble fibrin network.  The fibrin network stabilizes the primary platelet 
plug, enabling it to withstand the rigors of blood flow during wound healing.  A growing 
number of studies suggest that abnormal fibrin structure makes clots overly stable or friable 
during this process, contributing to an individual’s risk of thrombosis and embolism [1-4].  
 Mechanisms of fibrin production and clot assembly have been elucidated primarily from 
studies in which a specific amount of thrombin is added to purified fibrinogen.  These studies 
have shown that the thrombin concentration present at the time of fibrin gelation influences 
fibrin clot structure [5-9].  Low thrombin concentrations produce porous clots composed of 
thick fibrin fibers, while high thrombin concentrations produce clots composed of a dense 
network of thin fibers.  Additional studies have correlated fibrin architecture with a clot’s 
resistance to mechanical and fibrinolytic disruption [8-11]. Clots composed of a dense 
network of thin fibrin fibers are more resistant to fibrinolysis compared to clots composed of 
a porous network of thick fibers.  In vivo, however, thrombin generation is a dynamic process 
in which the concentration of thrombin actively changes during the reaction course in accord 
with the local conditions.  Importantly, and in contrast to in vitro experiments initiated by the 
addition of exogenous thrombin to fibrinogen, thrombin generation in vivo is localized to a 
cell surface.  A recent study using real-time videomicroscopy demonstrated that the 
procoagulant activity of tissue factor-bearing cells regulates the fibrin formation rate up to 
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200 ?m from the cell surface, but does not modulate clot growth further from the cell [12].  
These findings suggest that the majority of thrombin generated on the initiating cell is 
spatially restricted to the region surrounding the cell, with limited diffusion to distal regions 
of the reaction milieu.  Thus, different regions of the growing thrombus are exposed to 
different concentrations of thrombin, as a function of time and distance from the source of 
prothrombinase activity.  Together, these findings suggest that when thrombin generation is 
localized to a cell surface, the resulting fibrin structure and stability reflects the specific 
procoagulant activity of the local cells, as well as the spatial location of the fibrin with 
respect to the cell surface. 
 In the current study, we examined fibrin structure and stability arising as a function of in 
situ thrombin generation on a cell surface.  To specifically focus on the role of the cell 
surface in determining clot structure, reactions were performed using purified proteins or 
plasma in the absence of platelets or microparticles.  We observed that fibrin architecture 
reflected the distance of fibrin from the cell surface, but not RGD-mediated interactions 
between the cell surface and the fibrin network.  This spatial heterogeneity in clot structure 
caused differential rates of clot formation and lysis proximal versus distal to the cell surface.  
Our results suggest that in situ thrombin generation on a cell surface modulates clot structure 
and stability in three dimensions. 
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3.3 Experimental section 
Proteins and materials 
 Dulbecco's modified Eagle's Medium (DMEM) with high glucose and L-glutamine, 0.05 
% Trypsin/EDTA, and phosphate buffered saline (PBS) were purchased from Gibco (Grand 
Island, NY).  Fetal bovine serum (FBS) was purchased from HyClone (Logan, UT).  
Chromozym Th (tosyl-gly-pro-arg-pNA) was from Boehringer-Mannheim (Indianapolis, IN).  
Synthetic peptide arg-gly-asp-ser (RGDS) and goat anti-rabbit peroxidase conjugate antibody 
were from Calbiochem (La Jolla, CA).  Prothrombin was generously provided by Dr. 
Dougald M. Monroe (University of North Carolina at Chapel Hill).  Thrombin, plasmin, corn 
trypsin inhibitor and factors Xa and Va were purchased from Haematologic Technologies 
Inc. (Essex Junction, VT).  Plasminogen- and fibronectin-free fibrinogen was purchased from 
Enzyme Research Laboratories (South Bend, IN).  Immortalized human fibroblasts (NHF1-
hTert) were provided by Dr. Marila Cordeiro-Stone (University of North Carolina at Chapel 
Hill). 
Preparation of AlexaFluor-488-labeled fibrinogen 
 AlexaFluor-488-labeled fibrinogen was prepared according to the manufacturer’s 
instructions (Invitrogen Corporation (Carlsbad, CA).  Labeled fibrinogen contained ~8 
molecules of dye/fibrinogen molecule.  The preparation was frozen in aliquots that were 
thawed only once before each experiment.  Turbidity measurements on fibrin formed in the 
presence or absence of labeled fibrinogen demonstrated that the inclusion of labeled 
fibrinogen did not affect polymerization (data not shown). 
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Cell culture 
 Immortalized human fibroblasts (NHF1-hTert) were grown in DMEM with 2 mM 
glutamine and 10% FBS at 37 °C in a humidified atmosphere
 
of 5% CO2.  Cultures were 
used at 80-95% confluence between passages 16-35. 
In situ thrombin generation and fibrin clot formation 
 The source of proteins and materials used is listed in the Supplemental Data section.  
Fibroblasts were washed with PBS and immediately incubated with factors Xa, Va, and 
CaCl2 (1 nM, 5 nM, 5 mM, final, respectively) and prothrombin (0.014 ?M or 1.4 ?M, final, 
as indicated) in HBS.  Thrombin generation was measured by quenching 10 μL aliquots of 
supernatant with 90 ?L of 20 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (pH 
7.4), 150 mM NaCl (HBS) containing 10 mM ethylenediamine tetraacetic acid (EDTA) and 
1 mg/mL bovine serum albumin (BSA).  Quenched reactions were diluted 1:10 in HBS 
containing 1 mM EDTA and 0.5 mM Chromozym Th.  The substrate cleavage rate (change 
in absorbance at 405 nm versus time) was measured using a SpectraMax 340PC microplate 
reader (Molecular Devices, Sunnyvale, CA).  Clot formation was monitored at 405 nm in 
parallel experiments that included 2 mg/mL fibrinogen [8, 13-15].  In reactions in which clot 
formation was initiated by exogenous thrombin addition, fibrinogen, CaCl2, and 2 nM 
thrombin (final) were pre-mixed and immediately added to the cells. 
Structural analysis by laser scanning confocal microscopy 
 Cells were grown to confluence on LabTek II Chamber uncoated #1.5 cover-glasses 
(Nalge Nunc International, Naperville, IL).  Clots were formed as above with the addition of 
10 μg AlexaFluor-488-labeled fibrinogen/150 ?L sample.  Clot formation was allowed to 
proceed until a constant final turbidity was reached in separate, parallel reactions.  In 
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experiments performed in the absence of cells, chambers were pretreated with SigmaCote 
(Sigma, St. Louis, MO) to eliminate surface effects of glass on the polymerizing fibrin [16].  
For lysis studies, cells were grown to confluence on MatTek uncoated #1.5 glass 35 mm 
dishes (Ashland, MA).  Clots were formed as above in the presence of 0.024 ?M plasmin 
(final).  Chambers were immediately scanned at the cell surface and 50 ?m above the cell 
surface and then every 15 seconds at each location until complete lysis.  
Conditions for laser scanning confocal microscopy  
 Clots were scanned with a Zeiss LSM5 Pascal laser scanning confocal microscope 
(LSCM) (Carl Zeiss, Inc) linked to a Zeiss Axiovert 200M microscope equipped with a Zeiss 
63x 1.4 NA oil immersion plan apo-chromatic lens. The 488 nm line of a medium power 
multi-line argon ion laser was used for excitation and a 505-530-nm band-pass filter for 
emission.  A computer equipped with Carl Zeiss software (v1.5) was used to operate the 
system.  Optical sectioning was achieved by closing the pinhole in the front of the detector to 
one airy unit. The zoom factor was 1. Thirty optical sections (1024 x 1024 pixels each) in 
three randomly-chosen locations were collected at 0.36-μm intervals in the z-axis at the cell 
surface (defined as when the cells were in focus using differential interference contrast 
microscopy) and 40-μm above the cell surface, thus covering a region 10.8-μm thick at and 
above the cell surface.  Image volumes were 146x146x10 ?m.  Single images were collected 
in 15.47 seconds.  Optical resolution was ~0.14 μm in the xy-plane and ~0.5 μm on the z-
axis. The sectioning interval in z was smaller than the calculated z-axis optical section 
resolution to achieve Nyquest sampling in z based on the Zeiss software calculation.  No 
correction was made for refractive index mismatch. 
Analysis of laser scanning confocal microscopy images 
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 Images were deconvolved using 3D deconvolution algorithms in AutoQuant’s 
Autodeblur version x1.4.1 (Media Cybernetics Inc., Bethesda, MD).  Fibrin network density 
and diameter were analyzed using Image J (version 1.37v, National Institutes of Health) by 
placing a random grid of 2 pixel crosses on individual slices (~121-144 crosses/slice).  
Network density was determined by counting fibers intersecting the middle of the crosses, 
divided by the total number of crosses.  Crosses placed over cells were subtracted from the 
total number of crosses.  Fiber thickness was measured on fibers intersecting a cross (~20 
fibers/slice).  For lysis experiments, images were deconvolved using 2D deconvolution 
algorithms in AutoQuant's Autodeblur.  Fibers were counted using the 
angiogenesis/endothelial tube formation application module in MetaMorph version 7.1.3.0 
(Molecular Devices, Dowington, PA).  
Western blot for integrin ?v and ?3 subunits 
 Cell lysates were prepared as described [17].  Thirty μg of total protein was separated by 
10% SDS-PAGE.  Integrin subunits were detected with rabbit anti-human ?v or ?3, 
generously provided by Dr. Susan S. Smyth (University of Kentucky), and goat anti-rabbit 
peroxidase-conjugated antibody.  Proteins were visualized with enhanced 
chemiluminescence detection (Amersham Biosciences, Piscataway, NJ). 
Preparation of platelet-free plasma 
 Blood was collected with informed consent under a protocol approved by the University 
of North Carolina Institutional Review Board.  Whole blood was drawn into 3.2% citrated 
saline and corn trypsin inhibitor (18.3 μg/mL, final) and centrifuged at 150xg for 10 minutes.  
The upper layer (platelet-rich plasma) was centrifuged at 13000xg for 10 minutes to make 
  64 
platelet-free plasma.  Platelet-free plasma (PFP) from 16 individuals with normal activated 
partial thromboplastin times were pooled to yield normal pooled platelet-free plasma (PFP).  
Clot formation in normal pooled plasma  
 Cells were grown to confluence on sterile glass chamber slides for LSCM and sterile 
Thermanox tissue culture cover slips (Miles Laboratories, Naperville, IL) or in eight well 
Permanox chamber slides (Nalge Nunc International, Rochester, NY) for transmission 
electron microscopy (TEM).  Cells were washed with PBS and clots were formed by 
incubating fibroblasts with re-calcified (10 mM, final) platelet-free plasma plus 10 μg of 
AlexaFluor-488-labeled fibrinogen for two hours 
Structural analysis by transmission electron microscopy 
 Clots were fixed overnight in 4% paraformaldehyde/0.15% glutaraldehyde in PBS.  Fixed 
clots were removed from
 
the wells, washed, embedded in LR white, and cross-sectioned (90 
nm) to visualize cells and fibrin.  Post-embedding immunogold labeling was performed by 
adding rabbit anti-human fibrinogen antibody (Dako Corporation, Carpinteria, CA) followed 
by goat anti-rabbit 20-nm gold-conjugated antibody (BBInternational, Lianishan, Cardiff) to 
confirm the identity of fibrin fibers in certain experiments.  Clots were imaged using a LEO 
EM910 transmission electron microscope (Carl Zeiss SMT, Peabody, MA) operating at 80kv.  
Digital images were recorded using a Gatan Orius CCD Digital Camera and Digital 
Micrograph 3.11.0 (Gatan INC, Pleasanton, CA). 
Statistical methods 
 Pair-wise comparisons were performed using a Student’s t-test; p < 0.05 was considered 
significant. 
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3.4  Results 
 The thrombin generation rate modulates the onset and rate of fibrin clot formation.  
We incubated human fibroblasts with factors Xa and Va and varied the prothrombin 
concentration to modulate the thrombin generation rate.  We monitored thrombin activity 
with a chromogenic substrate and observed a 41-fold increase in the thrombin generation rate 
in the presence of 1.4 vs. 0.014 ?M prothrombin (p < 0.007) (Table 3.1, Figure 3.1a).  To 
determine the effect of thrombin generation rate on clot formation, plasma fibrinogen (2 
mg/mL, final) was included in reactions and clot formation was monitored by turbidity.  Clot 
formation during high thrombin generation rates (1.4 ?M prothrombin) exhibited a shortened 
onset and 2.2-fold increased polymerization rate compared to clot formation during low 
thrombin generation rates (Table 3.1, Figure 3.1b).  Interestingly, despite the significant 
difference in onset and fibrin polymerization rate, clots formed during high thrombin 
generation rates had only slightly lower final turbidities than clots formed during low 
thrombin generation rates (Table 3.1, Figure 3.1b).  Such a non-linear relationship between 
fibrin polymerization rate and final turbidity has been observed in previous studies performed 
in the presence and absence of cells [5-9, 14, 15, 18].  Nonetheless, because the onset and 
polymerization rate are indicative of fibrin structure, these measurements suggested that clots 
formed during high thrombin generation rates had a different structure than clots formed 
during low thrombin generation rates. 
 Cells modulate fibrin structural characteristics in three dimensions.  We next 
examined the fibrin structure of clots formed during in situ thrombin generation on the cell 
surface using LSCM.  LSCM permits the investigation of unfixed, fully hydrated samples; 
data from this technique can be used to recreate three-dimensional images permitting  
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TABLE 3.1.  Properties of clots formed by in situ thrombin generation 
 Thrombin 
Generation Rate 
(nM/min) 
Clotting Onset 
(seconds) 
Fibrin Polymerization 
Rate (mOD/min) 
Final 
Turbidity at 
405 nm 
0.014 ?M 0.402 ± 0.11 77 ± 5.0 77 ± 7.2 0.589 ± 0.12 
1.4 ?M 16.3 ± 5.44 33 ± 14.6 168 ± 20.3 0.536 ± 0.11 
P <0.007 < 0.008 < 0.002 NS 
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Figure 3.1.  Varying the prothrombin concentration affects thrombin generation and 
clot formation on human fibroblasts.  Factors Xa, Va, CaCl2, and 0.014 ?M prothrombin 
(circles) or 1.4 ?M prothrombin (squares) were incubated with confluent fibroblasts in the 
presence or absence of fibrinogen, as described in the Experimental section.  A) Thrombin 
generation.  B) Clot formation.  The inset in panel B shows an enlargement of the first 2 
minutes of the clotting reaction.  The data (± standard deviation) shown are from one 
experiment, representative of three independent experiments.  
B
A
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structural analysis as a function of focal depth within the sample.  LSCM enabled us to 
examine inter-clot differences in structure as a function of prothrombinase activity, as well as 
intra-clot differences in structure as a function of spatial location within the clot. 
 As anticipated from the polymerization data, clots formed during high thrombin 
generation rates had ~15% thinner fibers and a 14% denser fibrin network than clots formed 
during low thrombin generation rates (compare Figures 3.2a, 3.2d with 3.2b, 3.2e, 
respectively, Table 3.2).  Remarkably, however, the network density was ~25% higher in 
regions proximal (0 - 10 ?m) versus distal to (40 - 50 ?m) the cell surface regardless of the 
thrombin generation rate (compare Figures 3.2a, 3.2b with 3.2d, 3.2e, respectively, Table 
3.2).  In contrast, fiber thickness did not change as a function of distance from the cell 
surface (Table 3.2).  Of note, however, fiber diameter (200-400 nm) is near the lower 
resolution limit for LSCM (~200 nm) [5, 19], such that subtle changes may not be apparent.  
Nonetheless, the spatial-dependence of fibrin density in clots formed during in situ thrombin 
generation on the cell surface suggested that cells modulate the three-dimensional structure 
of the clot. 
 In situ thrombin generation on fibroblasts modulates fibrin structural 
characteristics independently of RGD-binding integrins.  The structural heterogeneity of 
clots formed over fibroblasts suggested that localization of thrombin generation on the cell 
surface and/or cellular interactions with the fibrin network influenced the clot’s structure.  
We therefore examined the influence of cellular receptors on fibrin structure in these clots.  
Previous studies have shown that cellular integrins bind fibrin(ogen) [20-22], and that the 
?v?3 and ?IIb?3 integrins can directly modulate fibrin structure on human umbilical vein 
endothelial cells (HUVEC) and platelets, respectively [23-25]. Since the fibroblasts used in  
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Figure 3.2.  In situ thrombin generation on the cell surface modulates clot structure in 
three dimensions.  Clots were formed as described in the Experimental section in the 
absence (a-f) or presence (g-i) of RGDS peptide.  Three-dimensional projections show clot 
architecture in 10-μm sections at (0-10 ?m) and above (40-50 ?m) the cell surface.  Each 
image is from one experiment, representative of 3-6 independent experiments.  Darker areas 
show increased fibrin density. 
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TABLE 3.2.  Fibrin structure in 10-μm sections 0-10 μm and 40-50 μm from the cell 
surface 
 
 Density 
(0 – 10 ?m) 
Density 
(40 – 50 ?m) 
P (0-10 
?m vs. 
40-50 
?m) 
Fiber 
Diameter 
(0 – 10 ?m) 
Fiber 
Diameter 
(40 – 50 
?m) 
P (0-
10 
?m 
vs. 
40-50 
?m) 
0.014 ?M 0.763 ± 0.025 0.568 ± 0.048 < 0.008 0.300 ± 
0.024 
0.311 ± 
0.032 
NS 
0.014 ?M + 
RGDS 
0.720 ± 0.027 0.569 ± 0.020 < 0.002 ND ND - 
P (± RGDS) NS NS - - - - 
1.4 ?M 0.856 ± 0.008 0.662 ± 0.052 < 0.02 0.263 ± 
0.002 
0.268 ± 
0.007 
NS 
1.4 ?M + 
RGDS 
0.866 ± 0.042 0.607 ± 0.054 < 0.003 ND ND  
P (± RGDS) NS NS - - - - 
2 nM 
thrombin 
0.715 ± 0.037 0.700 ± 0.060 NS 0.313 ± 
0.013 
0.311 ± 
0.014 
NS 
2 nM 
thrombin + 
RGDS 
0.683 ± 0.012 0.663 ± 0.040 NS ND ND - 
P (± RGDS) NS NS - - - - 
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our study expressed both ?v and ?3 subunits (data not shown) [20-22, 26], we examined the 
influence of ?v?3 and other RGD-binding integrins on fibrin architecture by comparing clots 
formed in the presence and absence of the integrin-blocking peptide, RGDS (500 ?M, final).  
This concentration of RGDS peptide inhibited platelet aggregation but did not alter the rates 
of thrombin generation or fibrin polymerization (data not shown).  As seen in the absence of 
RGDS, the mean network density was ~25% higher in regions proximal (0 – 10 ?m) versus 
distal (40 – 50 ?m) to the cell surface (Table 3.2).  The mean network density was identical 
with and without RGDS (compare Figures 3.2d and 3.2e with 3.2g and 3.2h, respectively, 
Table 3.2), suggesting that neither ?v?3, ?IIb?3, nor other RGD-binding integrins caused the 
spatially-dependent morphology seen in clots formed during in situ thrombin generation. 
 To further confirm that RGD-binding integrins did not influence fibrin structure in clots 
formed on fibroblasts, we triggered clot formation with the addition of a single, 
monodispersed thrombin concentration to a fibrinogen/calcium solution.  These reactions 
bypass in situ thrombin generation, so that fibrin structure arises from a uniform thrombin 
concentration distributed throughout the reaction.  Previous studies of clots formed over 
HUVEC [24] and platelets [25] demonstrated that integrin-mediated influences on fibrin 
structure are detectable following exogenous thrombin addition.  Under these conditions, the 
mean network density in regions proximal (0-10 ?m) and distal (40-50 ?m) to the cell 
surface were indistinguishable (Figures 3.2c, 3.2f, Table 3.2), and addition of RGDS peptide 
did not alter the fibrin appearance (compare Figures 3.2f and 3.2i, Table 3.2).  These findings 
suggest that in situ thrombin generation on the cell surface induces the formation of spatially-
dependent fibrin morphology independent of RGD-binding integrins. 
  72 
 In situ thrombin generation on fibroblasts modulates fibrin structure.  To precisely 
determine the distance over which cells influence fibrin structure, we quantified fiber 
diameter and network density in successive images recorded as the focal plane of the LSCM 
progressed from 0 to 10 and 40 to 50 ?m from the cell surface (Figure 3.3).  As seen in the 
10-?m sections, fiber diameter measurements did not change as a function of distance from 
the cell surface in any clots examined (Figure 3.4), possibly reflecting LSCM resolution 
limits.  Conversely, clots formed during in situ thrombin generation, exhibited a significant 
decrease in network density (48% ± 10.7% and 51% ± 2.9% for 0.014 μM and 1.4 μM 
prothrombin, respectively) between 0 and 10 ?m from the cell surface, and a minor further 
decrease in network density between 40 and 50 ?m from the cell surface (Figure 3.3).  The 
morphology was seen in both the presence and absence of RGDS peptide.  Surprisingly, 
although the global network was similar proximal and distal to the cell surface in clots 
formed by exogenous thrombin addition (Figure 3.2, Table 3.2), we did find a local decrease 
in network density (~11%) between 0 and ~4 ?m in these clots (Figure 3.3), in both the 
presence and absence of RGDS peptide (Figure 3.5).  To confirm that the decrease was not 
due to non-specific chamber surface effects on the fibrin network, we formed clots in the 
absence of cells via exogenous thrombin addition to a fibrinogen/calcium solution.  Under 
these conditions, clots showed no change in network density from 0-50 ?m from the surface 
(Figure 3.3).  Together, these findings suggest that fibroblasts modulate fibrin structure over 
a short distance (< 4 ?m) via a non-RGD-dependent receptor, however, thrombin generation 
is the predominant determinant of fibrin structure in these clots. 
 In situ thrombin generation on a cell surface modulates the rates of fibrin formation 
and lysis as a function of distance from the cell surface.  Since the thrombin  
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Figure 3.3.  Fibrin structure is determined by the distance from the cell surface.  A) 
Images from one experiment in which clots were formed by combining factors Xa, Va, II, 
fibrinogen, and CaCl2 (1 nM, 5 nM, 1.4 ?M, 2 mg/mL, and 5 mM, respectively) as described 
in the Experimental section.  a) Differential interference contrast image.  b - k) Individuals 
slices every 1.08 ?m in the z-plane:  b) 0, c) 1.08, d) 2.16, e) 3.24, f) 4.32, g) 5.4, h) 6.48, i) 
7.56, j) 8.64, and k) 9.72 μm from the cell surface.  Darker areas show increased fibrin 
density. B) Fibrin network density (± standard error) was determined as described in 
Experimental section in the presence of cells with 0.014 ?M prothrombin (circles), 1.4 ?M 
prothrombin (squares), 2 nM thrombin (diamonds), or in the absence of cells with 2 nM 
thrombin (triangles). The data are an average of three independent experiments. 
A
B
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Figure 3.4.  Fiber diameter is not influenced by distance from the cell surface.  Fibrin 
fiber diameter (± standard error) was determined as described in the Experimental section in 
the presence of cells with 0.014 ?M prothrombin (circles), 1.4 ?M prothrombin (squares), or 
2 nM thrombin (diamonds). The data are an average of three independent experiments. The 
data are an average of three independent experiments. 
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Figure 3.5.  Fibrin density is determined by the distance from the cell surface and is not 
altered by the presence or absence of RGDS peptide.  Fibrin network density (± standard 
error) was determined as described in the Experimental section in the absence and presence 
(open and closed symbols, respectively) of clots formed over fibroblasts with A) 0.014 ?M 
prothrombin, B) 1.4 ?M prothrombin, or C) 2 nM thrombin. 
A B. 
C
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concentration modulates the fibrin formation rate and resistance to fibrinolysis [5-11], we 
explicitly determined how in situ thrombin generation on the cell surface affected the spatial 
and temporal aspects of fibrin formation and lysis.  We incubated fibroblasts with purified 
prothrombinase and included plasmin at the reaction start to uniformly disperse plasmin 
throughout the clotting milieu.  In this assay, fibrin formation competes with lysis, and fibrin 
formation and lysis occur as a function of the thrombin generation rate and network quality 
[8, 15, 27]. 
 During low thrombin generation rates (0.014 ?M prothrombin), fibrin formed proximal, 
but not distal to the cell surface within 50 seconds (Figure 3.6).  After two minutes, fibrin 
was present proximal and distal to the cell surface.  Fibrin distal to (50 ?m above) the cell 
surface lysed 328 ± 82 seconds prior to lysis at the cell surface.  During high thrombin 
generation rates (1.4 ?M prothrombin), we observed immediate fibrin formation near the cell 
surface < 15 seconds after clotting was initiated (Figure 3.6).  As in reactions with low 
thrombin generation, fibrin appearance proximal to the surface preceded that distal to (50 ?m 
above) the cell surface, and fibrin lysed above the cell surface 449 ± 47 seconds prior to lysis 
near the cell surface.  Interestingly, the lysis rate (decrease in fiber number/?m2 versus time) 
was higher near versus distal to the cell surface, consistent with prior observations that fibers 
in clots with a tight network lyse more slowly than those in a loose network [9]. 
 In contrast, clots produced by exogenous thrombin addition demonstrated essentially 
simultaneous fibrin formation through the chamber at ~50 seconds (Figure 3.6).  The large 
variability in clots formed by exogenous thrombin addition likely results from the technical 
challenge of initiating clot formation by thrombin addition; fibrin formation begins as the 
solution is being transferred, causing variability in clot structure.  Regardless, this control  
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Figure 3.6.  Clot formation and lysis are determined by the distance from the cell 
surface.  Factors Xa, Va, prothrombin, fibrinogen, and CaCl2 were combined in the presence 
of plasmin, as described in the Experimental section.  A) Images are from one experiment, 
representative of four independent experiments.  The circular lysis pattern reflects the 
distribution of light power across the lens (30% greater in the center than at the periphery at 
63X oil objective).  B) Change in the fiber number over time (± standard error, n = 4 - 6) in 
clots formed over cells with 0.014 ?M prothrombin (circles), 1.4 ?M prothrombin (squares), 
or 2 nM thrombin (diamonds), at (open symbols) and above (closed symbols) the cell 
surface.  C) Fiber formation was defined as the first appearance of fibers in the field of view.  
D) Fiber lysis was defined as the disappearance of all fibers in the field of view. 
A
B C. D
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experiment shows that differences in the rates of fibrin formation and lysis proximal versus 
distal to the cell surface were not simply due to differences in the plasmin distribution or 
release of plasmin inhibitors from the cell.  Together these findings demonstrate that 
thrombin generation on a cell surface increases fibrin formation and resistance to lysis near 
the cell surface versus distal regions within the clot. 
 Cells modulate the network density of plasma clots.  Finally, we examined whether in 
situ thrombin generation on fibroblasts modulated the three-dimensional structure of plasma 
clots.  Clots were formed as described in Methods, and fibrin density was examined using 
LSCM and TEM. As depicted in Figure 3.7, plasma clots exhibited denser fibrin network 
near the fibroblast surface versus 50 ?m above the cell surface.  The denser network was not 
abolished by addition of RGDS peptide, suggesting RGDS-binding integrins did not mediate 
this interaction.  TEM confirmed these findings, demonstrating 4-fold more fibers proximal 
(~1 ?m) versus distal to (~5 ?m away) the cell surface (Figure 3.7c-3.7d).  In contrast, clots 
formed in the absence of cells (via slow contact initiation) demonstrated a uniform 
distribution of thicker fibers.  These findings support our LSCM observations and 
demonstrate that in situ thrombin generation on a cell surface modulates plasma clot 
structure. 
3.5  Discussion 
 Previous studies have made three basic observations with regard to fibrin clot formation 
and stability.  First, blood coagulation is spatially non-uniform, with extrinsic and intrinsic 
activities differentially modulating the initiation and propagation of fibrin formation in space 
[12].  Second, the concentration of thrombin present during fibrin gelation dictates the 
architecture of the fibrin clot [5-9].  Third, the fibrin clot quality influences its susceptibility 
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Figure 3.7.  Cells modulate the network density of plasma clots.  Re-calcified PFP was 
incubated with or without fibroblasts, as described in the Experimental section.  A) Three-
dimensional projections show clot architecture in 10 ?m sections at (0-10 μm) and above 
(40-50 μm) the cell surface.  Each image is from one experiment, representative of 2 
independent experiments.  B) Fibrin network density (± standard deviation) in the absence 
and presence (open and closed symbols, respectively) of 500 μM RGDS.  C) TEMs of clots 
formed in the presence or absence of fibroblasts.  In both images, the bottom of the reaction 
chamber is oriented at the bottom of the image.  Bar = 1 ?m.  D) Fibrin fibers (black dots) 
were counted on micrographs recorded at 6300X by placing a 1-μm thick box parallel to the 
cell surface 0.25 μm and 5 μm from the cell surface and counting fibers inside the box.   
BA
DC
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to fibrinolysis [8-11].  Together these observations suggest that when thrombin generation is 
localized to a cell surface, the structure and stability of the resulting clot depends on cellular 
procoagulant activity and the location within the clot with respect to the cell surface.  In the 
current study, we examined the influence of in situ thrombin generation on a cell surface on 
the spatial dynamics of fibrin clot formation, structure, and lysis.  Our findings demonstrate 
that in situ thrombin generation on a cell surface causes the formation of a structurally 
heterogeneous clot, with a denser fibrin network that is resistant to fibrinolysis proximal to 
the cell surface compared to distal regions of the clot.  These novel findings demonstrate the 
importance of the cell as a site of localized procoagulant activity in determining clot structure 
and stability. 
 The predominant mechanism causing the spatially-heterogenous morphology is likely 
due to differential rates of thrombin generation at and above the cell surface.  Thrombin 
generation at the cell surface is accelerated by lipid, which offers a ~6-fold increase in the 
Vmax relative to the absence of lipid (at sites distal to the surface) [28].  Additionally, both 
mathematical simulations and in vitro studies predict that the diffusional limit of 
procoagulant enzymes through the fibrin/platelet layer limits thrombus height [29, 30].  Our 
experiments were performed under static conditions (lack of flow), however, this 
morphology may be enhanced by the removal of thrombin distal to the cells by flowing blood 
[30].  The movement of thrombin away from the cell surface is likely limited directly by the 
diffusion rate and indirectly by thrombin binding sites on fibrin, further impeding its progress 
through the gel matrix.  Thus, the influence of the fibrin network quality on thrombus growth 
is likely to be complex.  Although the fibroblasts used in our study express fibrinogen-
binding integrin subunits (?v and ?3), we did not see an effect of these subunits on fibrin 
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structure.  This lack of integrin effect contrasts that previously seen on platelets and HUVEC 
[23-25], but may reflect decreased relative density of integrins on the surface of fibroblasts 
versus other cells.  We observed a minor effect of the cells on fibrin structure in clots formed 
by exogenous thrombin addition that was not blocked by RGD-containing peptides.  Besides 
integrins, vascular endothelial-cadherin [31] and intercellular adhesion molecule-1 (ICAM-1) 
[22, 32] also bind fibrin(ogen).  Preliminary experiments demonstrate that ICAM-1-blocking 
antibodies do not alter fibrin structure, suggesting that ICAM-1 does not influence fibrin 
structure on these cells.  Further studies are ongoing to identify the nature of these 
interactions. 
 Cellular procoagulant activity is determined by expression of pro- and anti-coagulant 
molecules.  For example, cells expressing high levels of tissue factor and phosphatidylserine 
support higher rates of thrombin generation [12].  Conversely, expression of tissue factor 
pathway inhibitor and thrombomodulin down-regulate thrombin generation [33, 34].  Cells 
also up- and down-regulate fibrinolysis via release of tPA and PAI-1, respectively [35], 
which may be expected to modulate lysis of fibrin proximal to the cell, prior to affecting 
fibrin distal to the cell.  As with pro- and anti-coagulant activities, expression of these pro- 
and anti-fibrinolytic activities are unique to different cells and vascular beds [36].  Moreover, 
pathologic triggers (e.g., infection, inflammation, stasis) differently modulate the expression 
of these activities on different cell types [36].  Given our findings, it is likely that different 
cell types in different vascular beds would uniquely and specifically regulate procoagulant 
and fibrinolytic activities following vascular injury or pathologic insult, and therefore, the 
formation, structure, and stability of fibrin.  The net influence of these cellular differences on 
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fibrin quality may account, at least in part, for vascular bed-specific fibrin deposition 
observed in various studies [37-39].   
 A growing number of studies suggest that abnormal fibrin structure contributes to an 
individual’s risk of arterial thrombosis [1-3].  We have previously shown that elevated 
prothrombin levels produce clots composed of an abnormally dense network composed of 
thin fibrin fibers [14], suggesting that abnormal fibrin structure contributes to the increased 
risk of venous thromboembolism in patients with the G20210A mutation [40].  It has also 
been hypothesized that abnormal clot quality contributes to the risk of pulmonary embolism 
following deep vein thrombosis [4].  Our study demonstrated fibrinolysis distal to the cell 
surface prior to proximal to the surface, consistent with processes thought to occur under 
normal conditions in vivo.  However, structurally inadequate regions within a clot, poor-
anchoring of intravascular clots to the vessel wall, or increased cell-derived fibrinolytic 
activity that triggers premature lysis of fibrin proximal to the cell surface may promote 
embolization in vivo.  Further studies are warranted to understand the relationship between 
fibrin structure, stability, and embolization.  
 In summary, our findings demonstrate for the first time that cellular procoagulant activity 
dictates clot structure and stability as functions of not only the rate of thrombin generation, 
but also the three-dimensional location of fibrin within the clot.  Specifically, during in situ 
thrombin generation, fibrin forms more quickly, assumes a denser network, and is relatively 
resistant to lysis proximal to the procoagulant cell surface versus distal.  This morphology 
can arise independently of direct interactions between cellular receptors and the fibrin 
network, but may be further modulated by cellular receptors on certain cells.  This study is a 
first step in understanding how cells contribute to fibrin formation.  Identifying specific 
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cellular influences on fibrin structure is essential for determining antithrombotic targets for 
preventing thrombus formation or stabilizing fibrin clots to prevent embolism. 
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Chapter 4 
The Role of Extravascular and Intravascular Cells on 
Thrombin Generation and Clot Formation  
 
 
4.1  Abstract 
 We have previously shown that localized, in situ thrombin generation on a cellular 
surface modulates the three-dimensional architecture of a fibrin clot and its stability.  In the 
present study, we have extended our observations by examining the role of different vascular 
cells in determining the three-dimensional architecture of the clot.  We first characterized the 
procoagulant and anticoagulant phenotypes of three different cell types: fibroblasts, aortic 
smooth muscle cells (SMC), and human umbilical vein endothelial cells (HUVEC).  
Fibroblasts supported rapid rates of thrombin generation (60.5 vs. 1.5 nM/min) and clot 
formation (238.5 vs. 56.5 mOD/min) compared to HUVEC.  Aortic SMC supported 
intermediate rates of thrombin generation (14.9 nM/min) and clot formation (138.4 
mOD/min).  To determine whether differences in the procoagulant and anticoagulant 
activities of the cells resulted in different clot architectures, we examined clot architecture 
proximal and distal to the cell surface using confocal microscopy.  Clots formed by 
fibroblasts were composed of densely packed (0.80 ± 0.01), thin fibers, while HUVEC 
produced clots composed of loosely woven (0.55 ± 0.02), thick fibers.  Similar to thrombin 
generation and clot formation, aortic SMC produced clots with an intermediate density (0.68 
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± 0.03) and thickness.  However, independent of the rate of thrombin generation, fibrin clots 
formed by all three cell types demonstrated a three-dimensional heterogeneity with denser 
regions of fibrin proximal to the cell surface compared to distal regions of the clot.  A 
GRGDSP peptide and ?3 antibody failed to inhibit the denser regions of fibrin proximal to 
the cell surface, indicating that in situ thrombin generation, not integrins, was responsible for 
the clot heterogeneity.  We then treated HUVEC with the inflammatory cytokine tumor 
necrosis factor alpha (TNF?) to modulate the procoagulant phenotype of the cells.  
Stimulated cells supported significantly higher rates of thrombin generation (9.5-fold, 
p<0.05) compared to unstimulated cells.  Clots formed by stimulated cells were composed of 
denser, thinner fibers compared to clots formed by unstimulated cells (0.72 vs. 0.55).  Fiber 
density was greater proximal to the cell surface compared to distal regions on both stimulated 
and unstimulated cells, and this increased density near the cell surface was independent of 
RGD-binding integrins.  Together, these findings suggest that fibrin architecture reflects the 
specific procoagulant activity of the local cells and that alteration of the cellular procoagulant 
phenotype by an inflammatory mediator significantly impacts thrombin generation and the 
resulting fibrin clot, providing a novel link of abnormal fibrin clot architecture to 
inflammation and thrombosis. 
4.2  Introduction 
 Previous studies shown that the thrombin concentration present at the time of fibrin 
gelation influences fibrin clot architecture.  These studies, conducted by adding single 
concentrations of purified thrombin to purified fibrinogen, have shown that low thrombin 
concentrations produce clots with thick fibrin fibers, and these clots are particularly 
susceptible to fibrinolysis.  In contrast, high thrombin concentrations form clots with thin 
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fibrin fibers, and these clots are more resistant to fibrinolysis [1-6].  These differences in 
fibrinolytic susceptibility have significant physiologic implications:  clots resistant to 
fibrinolysis are prone to thrombosis, whereas clots that are susceptible to fibrinolysis are 
prone to premature lysis and bleeding [7].  In vivo, however, thrombin is actively generated 
on a cell surface, resulting in a dynamically changing thrombin concentration.  Therefore, to 
fully appreciate the role of thrombin in determining clot structure, it is important to examine 
how in situ thrombin generation influences fibrin clot structure. 
 In vivo, thrombin generation involves interactions between cells, including tissue factor 
(TF)-bearing cells and platelets, and soluble components of plasma such as coagulation 
factors [8].  The ability of cells to support thrombin generation is determined by their 
expression of pro- and anticoagulant activities.  TF exposure initiates thrombin generation, 
while phosphatidylserine exposure is necessary to support robust thrombin generation 
through prothrombinase activity [8, 9].  Expression of antithrombotic molecules, including 
tissue factor pathway inhibitor (TFPI) and thrombomodulin (TM), down-regulates thrombin 
generation by negatively regulating TF and cofactor activity, respectively [10-12].  Because 
the relative expression of these properties is highly cell-specific, different cells differ in their 
expression of net procoagulant activity (thrombin generation) [13].  For example, fibroblasts 
and smooth muscle cells provide a highly procoagulant surface, while endothelial cells 
support lower rates of thrombin generation [14-16].  Furthermore, studies have demonstrated 
that disturbances in the innate procoagulant activity of cells through inflammatory cytokine 
stimulation can change the net procoagulant activity of the cells, possibly promoting 
thrombosis [17-19].  While most studies have focused on cell-mediated thrombin generation, 
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few studies have examined how different vascular cells influence clot formation, 
architecture, and fibrinolytic stability. 
 In our previous work, we demonstrated that in situ thrombin generation on the cell 
surface produced clots with a significantly denser fiber network in a 10-?m region proximal 
versus distal to (40 – 50 ?m) the cell surface [20].  Furthermore, the fibrin network lysed 
more rapidly distal versus proximal to the cell surface, suggesting that the clot structural 
heterogeneity affected its fibrinolytic stability [20].  Together, these findings suggest that 
when thrombin generation is localized to a cell surface the quality of the fibrin network is 
determined by the procoagulant phenotype of the local cell population.   In the current study, 
we extended our previous work on the role of cellular procoagulant activity in determining 
fibrin clot architecture by examining several cell types that support different levels of 
thrombin generation:  human dermal fibroblasts, human aortic smooth muscle cells (SMC), 
and human umbilical vein endothelial cells (HUVEC).  Furthermore, we investigated how 
inflammatory cytokines alter the procoagulant phenotype of endothelial cells and the 
resulting effect on fibrin clot architecture.  To focus on the connection between cell surface 
thrombin generation and clot architecture, the clotting reactions were studied in platelet-free 
plasma in the absence of flow.  We observed that cellular procoagulant activity modulates the 
structural characteristics of the clot.  We further observed that the fibrin architecture of clots 
formed over these cell types reflects the distance from the cell surface, but not integrin-
mediated interactions. 
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4.3  Experimental section 
Proteins and materials 
 Dulbecco's modified Eagle's Medium (DMEM) with high glucose and 2 mM L-
glutamine, 0.05% trypsin/ethylenediamine tetraacetic acid (EDTA), and phosphate-buffered 
saline (PBS) (10 mM phosphate and 150 mM NaCl, final) were purchased from Gibco 
(Grand Island, NY, USA).  Fetal bovine serum (FBS) was purchased from HyClone (Logan, 
UT, USA).  Fluorogenic substrate for thrombin (Z-Gly-Gly-Arg-AMC), and thrombin 
calibrator (?2-macroglobulin/thrombin) were from Diagnostica Stago (Parsippany, NJ, 
USA).   Pefachrome PCa (d-lys-pro-arg-pNA, a chromogenic substrate for activated protein 
C), Pefachrome FXa (CH3OCO-d-cha-gly-arg-pNA, a chromogenic substrate for factor Xa), 
and Chromozym Th (tosyl-gly-pro-arg-pNA, a chromogenic substrate specific for thrombin) 
were purchased from Pentapharm (Basel, Switzerland).  AlexaFluor-488 protein labeling kit 
was purchased from Invitrogen Corporation (Carlsbad, CA, USA).  A mouse anti-human 
thrombomodulin antibody was purchased from Dako Corporation (Carpinteria, CA, USA).  
The synthetic peptides GRGESP (H-Gly-Arg-Gly-Glu-Ser-Pro-OH) and GRGDSP (H-Gly-
Arg-Gly-Asp-Ser-Pro-OH) were purchased from Anaspec (San Jose, CA, USA).  A goat 
anti-mouse and a goat anti-rabbit peroxidase conjugate antibody were purchased from 
Calbiochem (La Jolla, CA, USA).  Heparin sodium salt, a non-immune mouse IgG antibody 
(MOPC-1), collagen, and the Rho-associated kinase (ROCK) inhibitor Y-27632 were 
purchased from Sigma-Aldrich (Saint Louis, MO, USA).  Prothrombin, anti-thrombin III, 
and the mouse monoclonal Fab fragment Reopro (Abciximab) were generously provided by 
Dr. Dougald M. Monroe (Department of Medicine, University of North Carolina at Chapel 
Hill).  The mouse anti-human extracellular signal-regulated kinase (ERK) 2 clone 1B3B9 and 
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recombinant human tumor necrosis factor alpha (TNF?) were purchased from Millipore 
(Temecula, CA, USA).  Corn trypsin inhibitor (CTI), thrombin, prothrombin-deficient 
plasma, and factors Va and Xa were purchased from Haematologic Technologies Inc. (Essex 
Junction, VT, USA).  Factor X, protein C, and plasminogen- and fibronectin-free fibrinogen 
were purchased from Enzyme Research Laboratories (South Bend, IN, USA).  Factor X and 
prothrombin were further prepared as described.  Rabbit anti-human ?v or ?3 antibodies were 
generously provided by Dr. Susan S. Smyth (Department of Medicine, University of 
Kentucky).  The mouse anti-human TF antibody (HTF-1) was generously provided by Dr. 
Steve Carson (University of Nebraska at Omaha) [21].  SFLLRN was purchased from 
SynPep (Dublin, CA, USA). 
Preparation of AlexaFluor-488-labeled fibrinogen 
 AlexaFluor-488-labeled fibrinogen was prepared as described [20].  Labeled fibrinogen 
contained ~8 mole fluorophore per mole of fibrinogen and did not affect fibrin 
polymerization at the concentration used (data not shown). 
Cell culture 
 An immortalized human fibroblast cell line (NHF1-hTert) was generously provided by 
Dr. Marila Cordeiro-Stone (Department of Pathology and Laboratory Medicine, University 
of North Carolina at Chapel Hill) [22].  Fibroblasts were grown in DMEM with high glucose 
and 2 mM L-glutamine with 10% FBS.  Primary human umbilical vein endothelial cells 
(HUVEC) and aortic smooth muscle cells (SMC) were purchased from Lonza Walkersville 
(Walkersville, MD, USA).  Primary HUVEC were grown in endothelial basal medium 
supplemented with bovine brain extract, hydrocortisone, human endothelial growth factor 
(hEGF), FBS (2%, final), and gentamicin/amphortericin-B.  HUVEC were pooled from three 
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donors (a mixed male/female population with two Caucasians and one Asian) and used 
between passages 3-10 to reduce phenotypic drift.  Primary aortic SMCs were grown in 
smooth muscle basal medium supplemented with hEGF, insulin, human fibroblast growth 
factor basic, FBS (5%, final) and gentamicin/amphotericin-B.  Aortic SMC cultures were 
from a single donor and were used between passages 3-10 to reduce phenotypic drift.  Cells 
were seeded at 7500 cells/well in 96-well tissue culture flat-bottom plates and allowed to 
grow to 80-95% confluence prior to assaying.  Cells were washed three times with PBS 
before use in experiments. 
Measuring TF activity 
 TF activity was measured by adding factor VIIa (0.1 nM, final) in the presence of CaCl2 
(3 mM, final) to the washed cell monolayer for 5 minutes in the presence of mouse anti-
human TF antibody or mouse IgG control (10 μg/mL, final).  After the addition of factor X 
(135 nM, final), the reaction was allowed to proceed at 37oC for 30 minutes.  Factor Xa 
generation was measured by incubating 75 μL of reaction supernatant with 75 μL of 
chromogenic substrate (final concentration: 0.5 mM Pefachrome FXa 1 mM EDTA in 
HEPES-buffered saline and bovine serum albumin (HBS/BSA: 20 mM HEPES [N-2-
hydroxyethylpiperazine-N?-2-ethanesulfonic acid], pH 7.4, 150 mM NaCl and 1 mg/mL 
bovine serum albumin). 
Measuring prothrombinase activity 
 Prothrombinase activity was assayed by adding factor Xa (1 nM, final), factor Va (5 nM, 
final), CaCl2 (5 mM, final), and prothrombin (1.4 μM, final) to a washed monolayer of cells.  
At timed intervals, 10 μL of reaction supernatant were removed and quenched with 90 μL 
HBS/BSA containing 10 mM EDTA.  Quenched reactions were then diluted 1:10 in HBS 
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containing 1 mM EDTA and 0.5 mM Chromozym Th.  The rate of thrombin generation was 
calculated as we have described [20]. 
Measuring activated protein C generation 
 Activated protein C (APC) generation assays were performed as described [12].  APC 
generation was detected by incubating 50 μL of quenched reaction with 50 μL of Pefachrome 
PCa (0.3 mM, final, in HBS with 0.1% polyethylene glycol and 10 mM EDTA), and the rate 
of substrate cleavage (change in absorbance at 405 nm versus time) for each sample was 
measured using a kinetic microplate reader.   
Determination of cell surface proteins by western blot analysis  
 Western blot analysis for expression of thrombomodulin and integrin subunits ?v and ?3 
were performed as described [23].  Proteins (40 μg total) were separated by 4-12% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to NitroBind Pure 
Nitrocellulose (GE Osmonics, Minnetonka, MN, USA).  The immunoblot was blocked in 5% 
nonfat milk from Carnation in 20 mM Tris-HCl [pH 7.4], 150 mM NaCl, and 0.05% Tween-
20 (TBST) for one hour at room temperature.  Thrombomodulin was detected by incubation 
with mouse anti-human thrombomodulin antibody (1:1000 in TBST) overnight at 4 °C.  The 
integrin subunits ?v and ?3 were detected by incubation with rabbit anti-human ?v and ?3 
antibody (1:500 in TBST).  The secondary antibody (goat anti-mouse peroxidase-conjugated 
or goat anti-rabbit peroxidase-conjugated) was diluted 1:2000 in TBST.  ERK-2 was 
visualized as a loading control using a mouse anti-human ERK-2 antibody at 1:2000 dilution 
followed by a secondary goat anti-mouse peroxidase-conjugated antibody at 1:2000.  
Proteins were visualized with an enhanced chemiluminescence detection kit (Amersham 
Biosciences, Piscataway, NJ, USA).   
  96 
Normal pooled plasma preparation 
 Blood was collected from 18 healthy individuals (20 to 45 years old, 50% female, 50% 
non-Caucasian) through a 21-gauge needle into a syringe and immediately transferred to 
sodium citrate/CTI (0.105 M, 3.2%, pH 6.5 sodium citrate and 18.3 ?g/mL CTI) to minimize 
contact activation [24].  Platelet-free plasma (PFP) was prepared by sequential centrifugation 
(150 x g for 15 minutes, and 13000 x g for 15 minutes), aliquoted, and snap-frozen in liquid 
nitrogen within two hours of blood collection.  Partial thromboplastin times (PTT) were 
measured on PFP collected from each individual in the absence of CTI.  Normal pooled PFP 
was prepared by pooling platelet-free plasma from individuals with a normal PTT.  PFP was 
analyzed for activity levels of factors V, VII, VIII, IX, X, XI, protein C, free protein S, and 
fibrinogen at UNC Hospitals McLendon Clinical Laboratory, and all were found to be in the 
normal reference range.  
Thrombin generation in normal pooled plasma 
 The thrombin generation test was performed by calibrated automated thrombography 
(CAT) using a Fluoroskan Ascent fluorometer (ThermoLabsystem, Helsinki, Finland) [25].  
For all experiments, 80 ?L PFP (final plasma concentration 67.7%) and 20 ?L of HBS/BSA 
were added to washed monolayers of cells and warmed to 37 °C.  Reactions were initiated by 
automatically dispensing 20 ?L of 2.5 mM fluorogenic substrate (417 ?M, final) in 0.1 M 
CaCl2 (16.7 mM, final) to each well and monitored at 37 °C with excitation and emission 
filters at 390 and 460 nm, respectively, every 20 seconds for 120 minutes.  All reactions were 
performed in triplicate in each experiment.  Reactions were calibrated against wells 
containing 20 ?L of ?2-macroglobulin/thrombin and 80 ?L PFP to compensate for substrate 
depletion and the inner filter effect [25].  The addition of the fluorogenic substrate, alone, to 
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the cell monolayer did not produce signal, suggesting none of the cell types examined 
expressed an endogenous activity that results in substrate cleavage (data not shown). 
 Thrombin generation was calculated using Thrombinoscope software version 3.0.0.29  
(Thrombinoscope BV, Maastricht, The Netherlands) by comparing arbitrary fluorescence 
units to a standard calibration curve prepared with known concentrations of thrombin.  The 
lag time was defined by the software as the first time point after the concentration of 
thrombin exceeded one-sixth of the peak height.  The time to peak corresponded to the time 
to formation of maximal thrombin peak height.  The peak height was the maximum 
concentration of thrombin formed during the assay.  The endogenous thrombin potential 
(ETP) was proportional to the area under the thrombin generation curve and represented the 
total amount of active thrombin formed during the assay [26]. 
Clot formation and lysis in normal pooled plasma 
 Clot formation assays were performed by incubating cells with re-calcified (10 mM, 
final) PFP (86.7% final plasma concentration).  In some assays, fibrinogen (2 mg/mL), CaCl2 
(5 mM, final) and thrombin (2 nM, final) were added to cells instead of plasma.  Exogenous 
thrombin addition to primary unstimulated and stimulated HUVEC caused cultures to lose 
their normal polygonal shape due to actin polymerization [27].  To prevent actin 
polymerization and cell contraction, confluent monolayers were treated for 30 minutes with 
the Rho-associated kinase inhibitor Y-27632 (10 μM, final) in culture media.  To examine 
clot fibrinolysis, in some reactions tissue plasminogen activator (250 ng/mL, final) was 
added at the beginning of the reaction.  Clot formation and lysis was detected by turbidity 
changes at 405 nm in a SpectraMax 340PC plate reader.  Clots formed over a platelet 
monolayer were performed by adhering gel-filtered platelets [28] (150,000 platelets/μL, 
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final) on collagen-coated (50 μg/mL, final) glass cover slips and activating the platelets with 
SFLLRN (50 μg/mL, final) in the presence of 0.136 μM Reopro or control IgG.  Platelets 
were allowed to adhere and activate for 30 minutes at 37oC before cover slips were washed 
with HBS/BSA to remove any non-adherent platelets.  Re-calcified (10 mM, final), normal 
PFP with Reopro or control IgG was then added to the platelets, and clot formation was 
allowed to proceed for 2 hours before clots were imaged.  In some reactions, fibrinogen (2 
mg/mL, final), CaCl2 (5 mM, final), and thrombin (2 nM, final) in the presence of Reopro or 
control IgG were added to the platelet monolayer to examine fibrin/platelet interactions in the 
absence of in situ thrombin generation. 
Preparation of fibrin clots for structural analysis by laser scanning confocal microscopy  
 Cells were seeded in Lab-Tek II Chamber #1.5 coverglass (Nalge Nunc International, 
Naperville, IL, USA) at 33,000 cells/well and grown to 80-95% confluence.  Clots were 
formed as described above with the addition of 10 μg AlexaFluor-488-labeled fibrinogen per 
150 μL of sample (3.2% of the total fibrinogen concentration).  In some reactions, the 
synthetic peptide GRGDSP, which blocks binding to RGD-mediated receptors or a control 
peptide GRGESP (500 μM, final) were included to examine fibrin-RGD integrin-binding 
interactions.  Clot formation was allowed to proceed until a constant final turbidity was 
reached based on separate, parallel reactions monitored in a SpectraMax 340PC plate reader. 
 Clots were imaged as described [20].  Optical resolution in the x-y plane was 0.14 ?m 
and 0.5 ?m in the z-axis, which is near the lower limit of resolution to measure the diameter 
of a fibrin fiber accurately; therefore, fibrin diameter was not included in structural analysis 
of the clot [1]. 
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Analysis of laser scanning confocal microscopy images 
 Images were deconvolved using 3D deconvolution algorithms in AutoQuant’s 
Autodeblur version x1.4.1 (Media Cybernetics Inc., Bethesda, MD).  Fibrin network density 
and diameter were analyzed using Image J (version 1.37v, National Institutes of Health) by 
placing a random grid of 2 pixel crosses on individual slices (~121-144 crosses/slice), as we 
have described [20].  Briefly, network density was determined by counting fibers intersecting 
the middle of the crosses, divided by the total number of crosses.  Crosses placed over cells 
were subtracted from the total number of crosses.  Fiber thickness was measured on fibers 
intersecting a cross (~20 fibers/slice). 
Preparation of fibrin clots for structural analysis by transmission electron microscopy  
 Segments of saphenous vein (2-6 cm) were obtained with informed consent from patients 
undergoing coronary artery bypass grafting under a protocol approved by the University of 
North Carolina Institutional Review Board.  Premedication, anesthesia, and heparin 
administration were done as per usual UNC operating room protocols.  After removal, the 
saphenous vein segments were placed into heparinized saline before being immediately taken 
to the laboratory where the vein was transferred into PBS and cut longitudinally down the 
mid-line, creating two vessel halves.  The vessel segments were then cut laterally and placed 
into individual chambers on a permanox slide, lumen side up.  The vessels were then washed 
five times with PBS, and re-calcified (10 mM, final) plasma was added to the vessel lumen in 
the presence of Abciximab or mouse IgG (0.136 μM, final).  After two hours, clots were 
fixed overnight in 4% paraformaldehyde/1% glutaraldehyde in PBS.  Fixed clots were 
removed from the wells, washed, and embedded in Epon for thin sectioning.  Clots were 
imaged using a LEO EM910 transmission electron microscope (TEM) (Carl Zeiss SMT, 
  100 
Peabody, MA) operating at 80 kV.  Digital images were recorded using a Gatan Orius CCD 
Digital Camera and Digital Micrograph 3.11.0 (Gatan INC, Pleasanton, CA).  Fibrin fiber 
density was determined by placing a 1-μm-thick box on micrographs taken at 6300x parallel 
to the cell surface at 0.25 μm and 5 μm away from the cell surface and counting fibers inside 
the box, as we have described [20]. 
Statistical methods 
 Continuous variables were expressed as mean ± standard error of the mean (SEM).  A 
one-way analysis of variance (ANOVA) with a Bonferroni post-hoc test was used to control 
for multiple testing.  Pair-wise comparisons were performed using Student’s t-test; p < 0.05 
was considered significant. 
4.4 Results 
 Fibroblasts, aortic SMC, and HUVEC support significantly different levels of TF 
activity and APC generation.  We first characterized the pro- and anti-coagulant 
phenotypes of intravascular (HUVEC) and extravascular (aortic SMC and fibroblast) cell 
types.  Consistent with previous studies [15, 29, 30], fibroblasts supported a 145-fold higher 
rate of factor Xa generation compared to HUVEC (p < 0.0001) and a 16-fold higher rate 
compared to aortic SMC (p < 0.0001).  Aortic SMC expressed a 9-fold higher rate of factor 
Xa generation compared to HUVEC (p < 0.001) (Table 4.1).  An anti-TF antibody (10 
?g/mL, final) reduced TF activity by 77% on fibroblasts (p = 0.005) and 68% on aortic SMC 
(p = 0.05) (Table 4.1).  Since the tissue factor antibody and rFVIIa were added at the same 
time, competition between rFVIIa and the anti-TF antibody for binding to TF prevented  
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TABLE 4.1.  Pro- and anticoagulant properties of different vascular cells 
 Fibroblasts Aortic SMC HUVEC 
   Unstimulated 4 hrs TNF? 
TF activity 
(mOD/min) 
    
- Anti-TF 
antibody 
52.9 ± 8.8$#^ 3.30 ± 0.74*# 0.33 ± 0.07*$^ 7.82 ± 1.63*# 
+ Anti-TF 
antibody 
12.0  ± 3.1+ 1.05 ± 0.37+ 0.21 ± 0.07 1.05 ± 0.36+ 
Prothrombinase 
activity (nM/at 
15 minutes) 
109.8 ± 18.0 118.7 ± 23.4 115.9 ± 12.4 115.9 ± 16.9 
Activated 
Protein C 
(mOD/min) 
0.47 ± 0.11#^ 1.46 ± 0.62 1.84 ± 0.27 1.95 ± 0.17 
 
+ significantly different from without anti-TF antibody 
* significantly different from fibroblasts (p <0.05) 
$ significantly different from aortic SMC (p <0.05) 
# significantly different from HUVEC (p <0.05) 
^ significantly different from HUVEC + TNF? (4 hrs) (p <0.05) 
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complete inhibition of TF activity.  HUVEC supported little TF activity at baseline, and 
addition of anti-TF antibody had no effect on factor Xa generation. 
 We then incubated confluent cell monolayers with factors Xa, Va, and prothrombin in the 
presence of CaCl2 and measured prothrombinase activity on each cell type.  As shown in 
Table 4.1, fibroblasts, aortic SMC, and HUVEC supported similar rates of thrombin 
generation, while in the absence of a lipid surface (no cells plated) little thrombin generation 
was observed (data not shown).   This finding suggests the cellular monolayer provides a 
critical and necessary component for thrombin generation. 
 Finally, we compared thrombomodulin expression and the ability of cells to support 
protein C activation.  Consistent with previous studies [31-33],  HUVEC and aortic SMC 
expressed thrombomodulin antigen, whereas fibroblasts did not (Figure 4.1).  HUVEC and 
aortic SMC supported higher rates of protein C generation than fibroblasts (4-fold, p = 0.001, 
and 3.2-fold, respectively) (Table 4.1).  These results suggest fibroblasts expressed a highly 
procoagulant phenotype, HUVEC supported a highly anticoagulant surface, and aortic SMC 
maintained an intermediate phenotype between fibroblasts and HUVEC. 
 Thrombin generation correlates with the cellular TF activity.  We examined how the 
sum of the pro- and anticoagulant activities of different cell types affects thrombin generation 
in plasma.  We measured thrombin generation in re-calcified, contact-inhibited plasma by 
calibrated automated thrombography (CAT).  Figure 4.2 depicts a representative experiment 
showing thrombin generation over time.  Consistent with the individual pro- and 
anticoagulant properties of these cells, thrombin generation on fibroblasts demonstrated a 
significantly shorter lag time (p = 0.01), higher rate (p < 0.0001), increased peak (p < 
0.0001), and shorter time to peak (p < 0.0001) than HUVEC or aortic SMC (Figure 4.2 and  
  103 
 
 
 
Figure 4.1.  HUVEC and aortic SMC, but not fibroblasts, express thrombomodulin.  
Western blot analysis for expression of thrombomodulin was performed as described [23].  
Proteins (40 μg total) were separated by 4-12% SDS gel electrophoresis.  TM was detected 
using mouse anti-human TM antibody.  ERK expression was used as a control.  Lanes are as 
follows:  1. aortic SMC, 2. HUVEC + TNF? (4 hrs), 3. HUVEC, and 4. fibroblasts. 
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Figure 4.2.  The sum of pro- and anticoagulant activities on each cell type modulates the 
rate of thrombin generation.  Thrombin generation was measured using CAT as described 
in the Experimental section.  Symbols are as follows:  fibroblasts (circles), aortic SMC 
(diamonds), HUVEC (squares), and HUVEC stimulated with TNF? for 4 hours (triangles). 
Data shown are from one experiment and are representative of at least four separate 
experiments. 
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TABLE 4.2.  Thrombin generation parameters supported by different cell types 
 
 Fibroblasts Aortic SMC HUVEC 
   Unstimulated 4 hrs TNF? 
Onset 
(minutes) 
1.66 ± 0.23$# 3.61 ± 0.60*# 
 
12.8 ± 1.8*$^ 
 
2.42 ± 0.15# 
 
Peak (nM) 
189.1 ± 8.1$#^ 
 
95.6 ± 6.6*# 
 
22.4 ± 6.4*$^ 
 
91.4 ± 13.8*# 
 
Time to Peak 
(minutes) 
4.8 ± 0.3$#^ 
 
10.1 ± 0.97*# 
 
27.6 ± 3.0*$^ 
 
9.0 ± 0.77*# 
 
Rate 
(nM/min) 
60.5 ± 4.0$#^ 
 
14.9 ± 1.9*# 
 
1.5 ± 0.36*$^ 14.3 ± 4.0*# 
 
 
* significantly different from fibroblasts (p <0.05) 
$ significantly different from aortic SMC (p <0.05) 
# significantly different from HUVEC (p <0.05) 
^ significantly different from HUVEC + TNF? (4 hrs) (p <0.05) 
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Table 4.2).  Thrombin generation on aortic SMC demonstrated a significantly shorter lag 
time (p < 0.0001), higher rate (p < 0.0001), increased peak (p < 0.0001), and shorter time to 
peak (p < 0.0001) than HUVEC (Figure 4.2 and Table 4.2). 
 Fibroblasts, aortic SMC, and HUVEC support different levels of fibrin formation 
and uniquely modulate clot structure.  Since fibroblasts, aortic SMC, and HUVEC 
supported different levels of procoagulant activities (thrombin generation), and since 
thrombin generation dictates fibrin clot architecture, we hypothesized that these cells would 
support the formation of clots with different fibrin architecture.  We incubated monolayers of 
fibroblasts, aortic SMC, and HUVEC with re-calcified, normal pooled PFP and examined 
fibrin clot formation by turbidity and the architecture of the resulting clots using LSCM.  
Consistent with our thrombin generation results, fibroblasts supported plasma clot formation 
with a rapid onset (1.52 ± 0.10 min) and fast polymerization rate (238.5 ± 16.1 mOD/min), 
which were both significantly enhanced compared to aortic SMC (2.38 ± 0.10 min and 138.4 
± 7 mOD/min, p < 0.0001) and HUVEC (22.4 ± 1.4 min, p < 0.0001 and 56.5 ± 7 mOD/min, 
p < 0.0001) (Figure 4.3 and Table 4.3).  Plasma clots formed by the highly procoagulant 
fibroblasts were composed of densely packed, thin fibers, while clots formed by HUVEC 
were composed of loosely woven, thick fibers (Figure 4.4, Table 4.4).  Clots formed by aortic 
SMC exhibited an intermediate density and fibrin fiber thickness, consistent with their 
intermediate procoagulant phenotype (Figure 4.4, Table 4.4). 
 TNF?-stimulated HUVEC support increased rates of thrombin generation and clot 
formation and form denser clots compared to unstimulated HUVEC.  Early studies 
observed that venous thrombi were composed of two regions:  a fibrin-dense region near the 
vessel wall and a platelet-rich thrombus away from the site of clot attachment, suggesting  
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Figure 4.3.  Cellular procoagulant activity dictates the onset and rate of fibrin clot 
formation.  Re-calcified (10 mM, final) normal pooled PFP was added to confluent 
monolayers of cells, and fibrin polymerization was monitored at room temperature by 
turbidity changes at 405 nm with a SpectraMax 340PC plate reader.  Symbols are as follows:  
fibroblasts (circles), aortic SMC (diamonds), HUVEC (squares), and HUVEC stimulated 
with TNF? for 4 hours (triangles).  Data (± standard deviation) shown are in duplicate from 
one experiment and are representative of at least four separate experiments.
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TABLE 4.3.  Properties of clots formed by in situ thrombin generation over different 
cell types 
 
 Fibroblasts Aortic SMC HUVEC 
   Unstimulated 4 hrs TNF? 
Clotting Onset 
(minutes) 
1.52 ± 0.10# 
 
2.28 ± 0.10*# 
 
22.4 ± 1.38*$^ 
 
 
2.06 ± 0.14# 
 
Fibrin 
Polymerization 
Rate 
(mOD/min) 
 
238.5 ± 16.2$#^ 
 
138.4 ± 7.01*# 
 
56.5 ± 6.2*$^ 
 
109.5 ± 13.0*# 
 
Final Turbidity 
at 405 nm 
0.822 ± 0.010 
 
0.842 ± 0.009* 
 
0.787 ± 0.008$ 
 
0.830 ± 0.022 
 
 
* significantly different from fibroblasts (p <0.05) 
$ significantly different from aortic SMC (p <0.05) 
# significantly different from HUVEC (p <0.05) 
^ significantly different from HUVEC + TNF? (4 hrs) (p <0.05) 
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Figure 4.4.  In situ thrombin generation on the cell surface modulates clot architecture 
in three dimensions.  Clots were formed as described in the Experimental Section in the 
presence of GRGDSP (500 μM, final) (I-L) or control peptide GRGESP (500 μM, final) (A-
H).  Three-dimensional projections show clot architecture in 10-μm sections at (0-10 ?m, E-
H)) and above (40-50 ?m, A-D) the cell surface.  Each image is from one experiment, 
representative of three independent experiments.  Darker areas show increased fibrin density. 
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TABLE 4.4.  Fibrin architecture from clots formed by in situ thrombin generation in 
10-μm sections 0-10 μm and 40-50 μm from the cell surface 
 
 Density 
(0 – 10 ?m) 
Density 
(40 – 50 ?m) 
P (0-10 ?m vs. 
40-50 ?m) 
Fibroblasts + 
GRDESP 
0.796 ± 0.014 0.515 ± 0.045 0.0001 
Fibroblasts + 
GRGDSP 
0.835 ± 0.010 0.527 ± 0.039 0.016 
P (± GRGDSP) NS NS - 
Aortic SMC + 
GRDESP 
0.683 ± 0.034 0.455 ± 0.06 1.95 x 10-06 
Aortic SMC + 
GRGDSP 
0.666 ± 0.056 0.446 ± 0.024 0.003 
P (± GRGDSP) NS NS - 
HUVEC + GRDESP 0.546 ± 0.015 0.306 ± 0.015 1.19 x 10-10 
HUVEC + GRGDSP 0.579 ± 0.066 0.364 ± 0.012 0.03 
P (± GRGDSP) NS NS - 
HUVEC + 4 hours 
TNF? + GRDESP 
0.723 ± 0.014 0.468 ± 0.004 7.40 x 10-10 
HUVEC + 4 hours 
TNF? + GRGDSP 
0.730 ± 0.003 0.475 ± 0.042 0.026 
P (± RGDS) NS NS - 
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coagulation was initiated on intact, but dysfunctional, endothelium[34, 35].  It has been 
proposed that inflammatory cytokines such as TNF? and interleukin-1? play a role in 
vascular dysfunction, up-regulating procoagulant activity and pathological clot formation 
[18].  To focus on the role of inflammatory mediators in vascular dysfunction and 
thrombosis, we examined how stimulating HUVEC with TNF? affected fibrin clot formation 
and architecture.  The inflammatory cytokine TNF? has been shown to stimulate 
procoagulant activity on HUVEC in a time-dependent mechanism [18].  Stimulating HUVEC 
for 4 hours with 1 nM TNF? significantly increased factor Xa generation (p = 0.001 versus 
untreated HUVEC) (Table 4.1).  This activity was inhibited by an anti-TF antibody (4 hours, 
p = 0.009).  Stimulating HUVEC with 1 nM TNF? for 4 hours did not affect prothrombinase 
activity (Table 4.1).  Consistent with previous studies [23, 33], HUVEC stimulated with 
TNF? for 4 hours expressed similar levels of thrombomodulin antigen (data not shown) and 
supported similar levels of protein C activation (Table 4.1) as unstimulated HUVEC.  
Together, these results suggest that when HUVEC are stimulated with TNF?, quiescent 
HUVEC switch from an anticoagulant phenotype to a procoagulant phenotype.   
 We next characterized the effects of TNF? stimulation of HUVECs on thrombin 
generation.  Stimulating HUVEC for 4 hours with 1 nM TNF? shortened the lag time (p < 
0.0001), increased the thrombin generation rate (p < 0.0001), increased the peak height (p < 
0.0001), and shortened the time to peak (p < 0.0001) compared to unstimulated HUVEC 
(Figure 4.2 and Table 4.2). 
 Clot formation on TNF?-stimulated HUVEC initiated more quickly (shorter onset, p < 
0.0001 for both) than clot formation on unstimulated HUVEC.  HUVEC treated for 4 hours 
with TNF? supported a significantly increased clot formation rate (p = 0.026) (Figure 4.3).  
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We also examined the architecture of clots formed by TNF?-stimulated HUVEC.  Clots 
formed by stimulated HUVEC had a denser fibrin network composed of thinner fibers than 
unstimulated HUVEC (Figure 4.4 and Table 4.4).  These findings suggest that activation of 
endothelial cells with inflammatory mediators has a significant impact on fibrin clot 
architecture. 
 In situ thrombin generation on all cell types modulates the spatial structural aspects 
of fibrin clot architecture, independently of fibrin-binding receptors.  We have 
previously shown that the thrombin density gradient established by thrombin generation 
localized to a cellular surface produces a fibrin structural gradient, with increased fibrin 
density near the cell surface versus distal to the cell surface [20].  Consistent with these 
observations, we observed a denser fibrin network proximal versus distal (50 ?m) to the 
surface of all cell types examined in the current study (Figure 4.4 and Table 4.4).  Fibrin fiber 
density decreased with increasing distance from the cell surface until approximately 6 ?m 
from the cell surface (Figure 4.5a), while fibrin architecture was uniform from 6 to 50 ?m 
above the cell surface (Figure 4.5a).  Despite the qualitative similarities between fibrin 
formed over fibroblasts, aortic SMC, and unstimulated and unstimulated HUVEC (a denser 
network formed near the cell surface than above it on all cell types), fibrin formed over 
fibroblasts was denser both proximal and distal to the cell surface, compared to aortic SMC 
and HUVEC, while aortic SMC supported denser clot formation compared to unstimulated 
HUVEC (Figures 4.4 and 4.5a, and Table 4.4).   
 In addition to the influence of the thrombin density gradient on fibrin architecture, 
previous studies have shown that when thrombin is added to fibrinogen in the presence of 
endothelial cells or platelets, interactions between fibrin and the ?v?3 or ?IIb?3 integrins,  
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Figure 4.5.  In situ thrombin generation on the cell surface modulates clot architecture 
in three dimensions.  A) Fibrin network density (± standard error) was determined as 
described in the Experimental Section in the presence of fibroblasts (circles), aortic SMC 
(diamonds), HUVEC (squares), and HUVEC stimulated with TNF? for 4 hours (triangles). 
The presence of 500 μM GRGDSP (open symbols) had no effect on fibrin clot architecture 
compared to control peptide (closed symbols) on fibroblasts (B), aortic SMC (C), HUVEC 
(D), and HUVEC stimulated with 1 nM TNF? for 4 hours (E).  Data (± standard deviation) 
shown are from at least two separate experiments. 
 
A. B. 
C. D. E. 
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respectively, can produce a dense network of thin fibrin fibers in the region immediately 
surrounding the cell [36-39].  We previously showed that the thrombin density gradient, and 
not integrin interactions, dictates fibrin architecture on fibroblasts [20]; however, the relative 
roles of thrombin gradient and integrin interactions have not been established for aortic SMC 
or unstimulated and stimulated HUVEC.  Indeed, on these cells, the spatial organization of 
the fibrin network may reflect a combination of ?v?3- and thrombin-mediated influences. 
 To investigate the potential role of integrins in clot formation, we first determined 
whether each of the three cell types expressed ?v or ?3 subunits.  Consistent with previous 
studies, fibroblasts, aortic SMC, and HUVEC expressed both ?v and ?3 antigens (Figure 
4.6).  Stimulating with TNF? did not increase expression of either subunit (Figure 4.6).  To 
determine whether ?v?3, ?IIb?3, or other RGD-binding integrins modulated fibrin 
architecture during in situ thrombin generation on each cell type, we repeated the clot 
formation assays in the presence of the GRGDSP peptide or a GRGESP control peptide (500 
?M, final) to block these interactions.  This concentration of GRGDSP fully inhibits RGD-
mediated interactions [36, 40] and blocked platelet aggregation via the ?IIb?3 RGD-binding 
integrin (data not shown).  GRGDSP peptide did not alter the rates of thrombin generation or 
fibrin polymerization (data not shown).  We observed that fibrin clot architecture was similar 
in the presence and absence of the GRGDSP peptide, with denser fibrin proximal versus 
distal to the cell surface for all cell types (Figures 4.4, and 4.5b-e and Table 4.4).  Moreover, 
fibrin density at the cell surface was identical to that seen in the absence of GRGDSP 
(Figures 4.4 and 4.5b-e and Table 4.4).  In addition, the presence of a clinically relevant 
concentration of the anti-?3 integrin Reopro (0.136 ?M) [39] had no effect on fibrin clot 
architecture (Figure 4.7).  In contrast, on platelets which bind fibrin through ?II?3 [37, 38],  
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Figure 4.6.  Fibroblasts, aortic SMC, and unstimulated and stimulated HUVEC express 
the integrin subunits ?v and ?3.  Western blot analysis for expression of the integrin 
subunits ?v and ?3 was performed as described [23].  Proteins (40 μg total) were separated 
by 4-12% SDS gel electrophoresis.  The integrin subunits ?v (A) and ?3 (B) were detected by 
incubation with rabbit anti-human ?v and ?3 antibodies.  ERK expression was used as a 
control.  The lower band seen on the ?v blot (130 kDa) is probably the heavy chain of the ?v 
subunit.  Lanes are as follows:  1. fibroblasts, 2. HUVEC, 3. HUVEC + TNF? (4 hrs), and 4. 
aortic SMC. 
A. B. 
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Figure 4.7.  The ?3 integrin modulates fibrin structure on platelets, but not on 
fibroblasts, aortic SMC, or HUVEC.  Clots were formed over fibroblasts, aortic SMC, and 
HUVEC as described in the Experimental Section in the presence of 0.136 μM Reopro (A-
E), an anti-?3 antibody, or control IgG (F-J).  Clots formed over a platelet monolayer (D-E, I-
J) were performed by adhering platelets (150000 platelets/μL, final) on collagen-coated (50 
μg/mL, final) glass cover slips and activating the platelets with SFLLRN (50 μg/mL, final) in 
the presence of 0.136 μM Reopro or control IgG.  Platelets were allowed to adhere and 
activate for 30 minutes at 37oC before cover slips were washed with HBS/BSA to remove 
any non-adherent platelets.  Re-calcified (10 mM, final), normal PFP with Reopro or control 
IgG was then added to the platelets, and clot formation was allowed to proceed for 2 hours 
before clots were imaged (E, J).  In some reactions, fibrinogen (2 mg/mL, final), CaCl2 (5 
mM, final), and thrombin in the presence of Reopro or control IgG were added to the platelet 
monolayer to examine fibrin/platelet interactions in the absence of in situ thrombin 
generation (D, I).  Images are from one experiment. 
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Reopro was able to reduce the fibrin density near the platelet surface during both in situ 
thrombin generation and when clot formation proceeded through exogenous thrombin 
addition (Figure 4.7).  These findings suggested that ?v?3, ?IIb?3, and other RGD-binding 
integrins did not cause the spatial morphology seen in fibrin clots formed during in situ 
thrombin generation on the cell surface of fibroblasts, aortic SMC, and HUVEC. 
 We further confirmed the absence of RGD-binding integrins and fibrin receptors by 
triggering clot formation on each cell type with the addition of a single, monodispersed 
concentration of thrombin to purified fibrinogen in the presence of calcium (Figure 4.8).  
These reactions bypass in situ thrombin generation, and fibrin formation occurs within a 
uniform thrombin concentration.  In these reactions, the fibrin architecture of the clots 
reflected the thrombin concentration used to initiate clotting; higher thrombin concentrations 
produced denser clots with thinner fibers compared to lower thrombin concentrations.  
However, these clots lacked the spatial morphology seen during in situ thrombin generation 
on the cell surface.  Rather, exogenous thrombin addition triggered the formation of 
homogenous fibrin distribution (density and fiber thickness) throughout the clot, both 
proximal to and 50 ?m above the cell surface.  GRGDSP peptide (500 ?M) did not alter the 
fibrin appearance in these clots (Figure 4.8 and Table 4.5).  In reactions with HUVEC, a Rho 
inhibitor (Y-27632) was added to prevent actin polymerization and cell contraction; however, 
this inhibitor does not prevent fibrin from interacting with ?3 integrins [41].   
 These results confirm that fibrin-binding receptors on human dermal fibroblasts, aortic 
SMC, and unstimulated and stimulated HUVEC did not influence fibrin architecture.  
Moreover, these results show that in situ thrombin generation on a cell surface is necessary  
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Figure 4.8.  RGD-binding integrins do not modulate clot architecture in three 
dimensions.  Clots were formed as described in the Experimental Section in the presence of 
GRGDSP (500 μM, final) (I-L) or control peptide GRGESP (500 μM, final) (A-H).  Three-
dimensional projections show clot architecture in 10-μm sections at (0-10 ?m, E-H) and 
above (40-50 ?m, A-D) the cell surface.  Each image is from one experiment, representative 
of two-three independent experiments.   
  119 
TABLE 4.5.  Fibrin architecture from clots formed by exogenous thrombin addition in 
10-μm sections 0-10 μm and 40-50 μm from the cell surface 
 
 Density 
(0 – 10 ?m) 
Density 
(40 – 50 ?m) 
P (0-10 ?m vs. 
40-50 ?m) 
Fibroblasts + GRGESP 0.715 ± 0.037 0.700 ± 0.060 NS 
Fibroblasts + GRGDSP 0.683 ± 0.01 0.664 ± 0.040 NS 
P (± GRGDSP) NS NS - 
Aortic SMC + 
GRGESP 
0.540 ± 0.034 0.539 ± 0.040 NS 
Aortic SMC + 
GRGDSP 
0.605 ± 0.107 0.585 ± 0.113 NS 
P (± GRGDSP) NS NS - 
HUVEC + GRGESP 0.713 ± 0.05 0.700 ± 0.045 NS 
HUVEC + GRGDSP 0.630 ± 0.102 0.615 ± 0.072 NS 
P (± GRGDSP) NS NS - 
HUVEC + 4 hours 
TNF? + GRGESP 
0.674 ± 0.106 0.680 ± 0.023 NS 
HUVEC + 4 hours 
TNF? + GRGDSP 
0.643 ± 0.044 0.645 ± 0.066 NS 
P (± GRGDSP) NS NS - 
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and sufficient to achieve dependent fibrin morphology and distinguish the architecture of 
clots formed by different cell types. 
 Fibrin clots formed over excised human saphenous vein demonstrate a denser 
network of fibers proximal to the cell surface.  We next examined whether fibrin clots 
formed in freshly isolated saphenous veins exhibited a spatial heterogenity similar to the 
pattern observed on primary cultures and our previous work [20].  Re-calcified normal PFP 
was added to the lumen of spare excised saphenous veins from patients undergoing coronary 
bypass surgery and allowed to clot for at least two hours before being fixed for TEM 
imaging.  Analysis of clots formed over the vessel segments revealed a higher density of 
fibrin fibers per area proximal to the endothelial cell surface (1.22 ± 0.122) compared to five 
microns away from the cell surface (0.46 ± 0.07) (Figure 4.9).  The addition of a ?3 antibody 
did not alter the density of fibrin fibers (Figure 4.9), suggesting in situ thrombin density was 
responsible for the higher density of fibrin proximal to the cell surface. 
 Cellular procoagulant activity dictates clot fibrinolysis.  Previously, we showed that 
cellular procoagulant activity dictates fibrinolysis by prolonging clot lysis proximal to the 
cell surface, where in situ thrombin generation causes an increase in the density of fibrin 
fibers [20].  To examine fibrinolysis of clots formed over different cell types, tissue-type 
plasminogen activator (tPA) (250 ng/mL, final) was added to re-calcified normal PFP, before 
the reaction was initated over the cells.  Clot formation and lysis were then monitored by 
changes in turbidity at 405 nm.  The addition of tPA to clot formation assays allows us to 
optically monitor fibrin formation and lysis in real-time.  In these assays, the initial onset of 
fibrin formation (initial rise in turbidity) is primarily dependent on the procoagulant activity 
of the cells, since tPA conversion of plasminogen to plasmin depends on fibrin formation  
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Figure 4.9.  Plasma clots formed on excised saphenous vein segments have a higher 
fibrin density near the cell surface.  A) Fibrin clots were formed over excised human 
saphenous vein segments as described in the Experimental Section.  Clots were then fixed in 
4% paraformaldehyde and 1% glutaraldehyde, embedded in Epon for thin sectioning, and 
examined using a transmission electron microscope.  Original magnification ? 6300; bar 
1 ?m. Pictures are representative of two independent experiments.   B) Fibrin fibers (black 
dots) were counted on micrographs recorded at 6300X magnification by placing a 1-μm-
thick box parallel to the cell surface 0.25 μm and 5 μm from the cell surface and counting 
fibers inside the box.  Data are representative of two separate experiments. 
 
A. B. 
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[42].  However, the peak turbidity reached and time to peak turbidity most likely indicate the 
time to maximum fibrin formation.  Therefore, conditions that promote a faster time to peak 
and higher peak turbidity result in a more stable fibrin network, whereas lower peak turbidity 
arises when plasmin generation overwhelms fibrin formation, accelerating fibrinolysis.   
 In these assays, fibroblasts supported rapid fibrin formation (13.00 ± 1.10 min) with a 
peak turbidity of 0.912 ± 0.005 (Figure 4.10 and Table 4.6).  Aortic SMC, with an 
intermediate procoagulant phenotype (Figure 4.10 and Table 4.6), had a slightly lower 
turbidity (0.850 ± 0.02) and slower time to peak turbidity (21.9 ± 2.62 min, p = 0.0002) 
compared to fibroblasts.  HUVEC had the lowest peak turbidity (0.780 ± 0.02, p < 0.0001) 
and longest time to peak turbidity (45.7 ± 7.24 min, p < 0.0001) compared to fibroblasts.  
However, stimulating HUVEC with 1 nM TNF? for 4 hours resulted in a faster time to peak 
turbidity (21.2 ± 0.73 min, p = 0.002) and higher peak turbidity that tended towards 
significance compared to unstimulated HUVEC (p = 0.065) and was not significantly 
different from aortic SMC (Figure 4.10 and Table 4.6).  Taken together, these findings 
suggest that the procoagulant phenotype of the cell can dictate fibrinolysis and further 
emphasize that modulating the endothelial cell phenotype through cytokine stimulation can 
alter formation and subsequent lysis of a fibrin clot. 
 Reducing TF activity on stimulated HUVEC reduces fibrin clot density.  Based on 
our initial cellular characterization, TNF?-stimulated HUVEC express significantly higher 
TF activity (p<0.0001) compared to unstimulated HUVEC (Table 4.1).  However, both cell 
types supported similar levels of prothrombinase activity (Table 4.1).  These findings in 
combination with earlier studies suggesting that TF inhibitors, including antibodies against 
TF [43], and active-site inhibited FVIIa (FVIIai) [44] reduce thrombus  
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Figure 4.10.  Cellular procoagulant activity dictates fibrin clot formation and lysis.  Re-
calcified (10 mM, final) normal pooled PFP was added to confluent monolayers of cells in 
the presence of 250 ng/mL tPA (final), and fibrin polymerization and lysis were monitored at 
room temperature by turbidity changes at 405 nm with a SpectraMax 340PC plate reader.  
Symbols are as follows:  fibroblasts (circles), aortic SMC (diamonds), HUVEC (squares) and 
HUVEC stimulated with TNF? for 4 hours (triangles).  Data (± standard deviation) shown 
are in duplicate from one experiment and are representative of at least four separate 
experiments 
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TABLE 4.6.  Properties of clots formed and lysed over different cell types 
Cell Type Onset 
(minutes) 
Peak Turbidity 
(Absorbance at 405 
nm) 
Time to Peak 
(minutes) 
Fibroblasts 1.40 ± 0.05#$^ 0.912 ± 0.005#^ 13.0 ± 1.10#$^ 
Aortic SMC 2.79 ± 0.17*#^ 0.850 ± 0.02# 21.8 ± 2.62*# 
HUVEC 22.5 ± 3.53*$^ 0.780 ± 0.02*$ 45.7 ± 7.25*$^ 
HUVEC + TNF?  
4 hours 
2.09 ± 0.16*#$ 0.842 ± 0.02 21.2 ± 0.73*# 
 
* significantly different from fibroblasts (p <0.05) 
$ significantly different from aortic SMC (p <0.05) 
# significantly different from HUVEC (p <0.05) 
^ significantly different from HUVEC 4 hours (p <0.05) 
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propagation and weight in animal models of arterial and venous thrombosis indicate that TF, 
and not prothrombinase activity, is an important target for antithrombotic agents.  To 
determine whether TF inhibition alters clot structure, unstimulated and stimulated HUVEC 
were treated with an anti-tissue factor antibody [21] (10 μg/mL, final) or a control IgG, and 
thrombin generation, clot formation, and clot structure were examined.  The addition of an 
anti-TF antibody to unstimulated HUVEC slightly prolonged the onset of thrombin 
generation and clot formation (Figure 4.11).  However, the addition of an anti-TF antibody to 
stimulated HUVEC delayed the onset of thrombin generation and decreased the peak height 
and the time to peak (Figure 4.11).  Furthermore, the addition of the antibody to stimulated 
cells increased the onset of clot formation.   
 We next examined the structure of the clots formed over unstimulated and stimulated 
cells in the presence of an anti-TF antibody.  The addition of the antibody to unstimulated 
HUVEC did not affect clot structure (Figure 4.11).  However, the addition of the antibody to 
HUVEC that were stimulated for 4 hours with TNF? dramatically reduced the density of the 
fibrin clot, resulting in clot densities similar to those of clots formed over unstimulated 
HUVEC (Figure 4.11). 
4.5  Discussion 
 When a stimulus disturbs the hemostatic system, formation of a hemostatic clot based on 
the size and extent of the injury is necessary to prevent the loss of blood.  Previous studies 
have demonstrated that the structure of the clot is dictated by the location of thrombin 
generation and the concentration of thrombin at the time of gelation [2, 4, 5, 20, 45].  
Furthermore, the quality of the fibrin network dictates the stability of the clot to mechanical 
and fibrinolytic disruption [5, 46].  Together these observations suggest that when thrombin  
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Figure 4.11.  TF inhibition prolongs the onset and reduces the rate of thrombin 
generation and clot formation, resulting in a less dense fibrin network. A) Re-calcified 
(10 mM, final) normal pooled PFP was added to confluent monolayers of cells in the 
presence of an anti-TF antibody (10 μg/mL, final) (open symbols) or IgG control (closed 
symbols) and thrombin generation was measured using CAT as described in the 
Experimental Section.  Data shown are from one experiment, representative of two 
experiments.  B) Re-calcified (10 mM, final) normal pooled PFP was added to confluent 
monolayers of cells in the presence of an anti-TF antibody (10 μg/mL, final) (open symbols) 
or IgG control (closed symbols), and fibrin polymerization was monitored at room 
temperature by turbidity changes at 405 nm.  Data shown are from one experiment.  C) Clots 
were formed as described in the Experimental Section in the presence of an anti-TF antibody 
(10 μg/mL, final) or IgG control.  Three-dimensional projections show clot architecture in 
10-μm sections at 0-10 ?m.  Each image is from one experiment. 
 
 
 
C. 
A. B. 
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generation is localized to a cell surface, the architecture and stability of the resulting fibrin 
clot depend on the location within the clot, with respect to the cell surface and the cellular 
procoagulant activity.  Elucidating the regulation mechanism(s) for cellular procoagulant 
activity and the conditions under which a clot forms will help determine why an individual is 
prone to bleeding (low thrombin, fibrinolysis-susceptible clots), or to thrombosis (high 
thrombin, fibrinolysis-resistant clots).  In the current study, we sought to examine the cellular 
properties that influence in situ thrombin generation on different cell surfaces and how they 
affect the spatial dynamics of clot formation.  
 Our results demonstrate that intravascular cells (endothelial cells) have an anti-coagulant 
surface with little TF expression, but strong ability to generate APC.  These cellular 
properties support low levels of thrombin generation and a prolongation in the onset and rate 
of clot formation, ultimately leading to the formation of a loosely-woven clot with thick 
fibers.  Furthermore, the clots formed over intravascular cells are less resistant to lysis by 
tPA, as seen by the longer time to reach maximum clot formation and lower peak turbidity.  
These results suggest intravascular cells express properties that are necessary to maintain the 
integrity of the vascular wall without promoting a thrombotic event. 
 However, if extravascular cells are exposed at the site of injury, the dynamics of clot 
formation change due to the different properties of extravascular cells, which regulate 
thrombin generation differently than intravascular cells.  We found that aortic SMC, which 
are present in the intimal layer of the blood vessel, supported faster rates of thrombin 
generation and clot formation compared to HUVEC due to higher levels of TF expression, 
resulting in a dense, more stable clot.  Fibroblasts, which are found in the outermost layer of 
the blood vessel, supported the fastest rate of thrombin generation, translating into a denser 
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network of thin fibers, and the most structurally stable clots formed by the three cell types 
examined.  This enhanced clotting triggered by fibroblasts is most likely due to the high 
expression of TF and the absence of the ability to down-regulate thrombin generation 
through APC generation.  Taken together, the cellular composition of the different layers of 
the blood vessel is designed to promote hemostasis, with different levels of thrombin 
generation and fibrin clot quality and stability depending on the degree of the initial injury.  
However, our results also suggest under pathologic conditions, such as the presence of 
inflammatory mediators, intravascular cells can shift from supporting hemostasis to 
promoting thrombosis by increasing TF expression and the rate at which thrombin is 
generated.  
 On all three cell types examined, we observed a denser fibrin network proximal to the 
cell surface compared to distal regions of the clot, supporting our earlier work that thrombin 
generation localized to a cellular surface dictates the three-dimensional structure of the clot 
[20].  In this study, we extended the generality of this observation, initially made on 
fibroblasts, to two additional cultured cells types as well as freshly excised human saphenous 
vein model.  These results suggest that localized thrombin generation dictates this pattern 
independent of the rate of thrombin generation or the total amount of thrombin generated.  
 Previous studies have shown that ?v?3 and ?IIb?3 modulate fibrin architecture following 
exogenous thrombin addition [36, 39]; however, these integrins did not modulate fibrin 
architecture on the primary cultures or saphenous vein segments used in our study.  Our 
results do not preclude the effect of these integrins on clots formed on other cell types; 
however, our findings suggest that the relative impact of these integrins on fibrin architecture 
is limited.  Other molecules expressed on the cell surface have been shown to bind 
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fibrin(ogen), including VE-cadherin and ICAM-1 [40, 47-50].  However, since these 
studies[40, 47-50] only observed fibrin binding and not structural changes in fibrin structure 
and because we did not observe spatially dependent fibrin morphology in clots formed by 
exogenous thrombin addition, our findings indicate that interactions between these molecules 
and fibrin(ogen) do not modulate fibrin architecture.   
 The current study contributes to our understanding of the role of platelets in the 
development of arterial thrombosis.  Platelets are likely the predominant site of thrombin 
generation in arterial clots, and anti-platelet agents are normally used in the treatment of 
arterial thrombosis [51].  We demonstrated that platelets were locally capable of organizing 
fibrin fibers into dense bundles when fibrin was formed using exogenous thrombin as well as 
during in situ thrombin generation.  However, the addition the anti-platelet agent Reopro at a 
clinically relevant dose [39] had a dramatic effect on the overall structure of the clots, 
reducing the density of fibrin proximal to the platelet surface.  On the other hand, Reopro had 
no effect on fibrin structure on the other cell types examined, correlating with the observation 
that potent platelet inhibitors fail to prevent the development of fibrin-rich venous clots [52].   
 The development of venous thrombosis has been hypothesized to involve changes in the 
vessel wall due to inflammatory mediators, resulting in endothelial cell activation.  By 
stimulating endothelial cells with the cytokine TNF?, we demonstrated a significant increase 
in TF expression and the rate of thrombin generation supported by the cells that was 
independent of changes in lipid expression.  The resultant increase in procoagulant activity 
produced clots with dense networks of thin fibers, similar to clots formed over aortic SMC.  
These results suggest inflammatory mediators such as TNF?, and IL-1? cause intravascular 
cells to express properties normally found on extravascular cells (increased TF expression), 
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predisposing an individual to venous thrombus development.  Interestingly, blocking the 
increased TF activity on TNF?-treated endothelial cells reverted the stimulated cells to 
quiescent intravascular cells, suggesting TF antagonists may have clinical benefit in reducing 
venous thrombosis [43] . 
 Importantly, our results provide a foundation for future studies involving different cell 
types from different vascular beds.  Our system allows for the examination of how cellular 
properties, such TF expression[53] , binding of TF-microparticles [54, 55], and TFPI and TM 
expression[13, 56], on endothelial cells from the arterial, venous, and microvascular 
circulation contribute to local thrombin generation and the architecture of the clot.  These 
studies are critical to understanding the role of the endothelium in vascular bed-specific 
thrombosis.  Furthermore, we are able to examine interactions between the fibrin clot and 
cells from the vessel wall during in situ thrombin generation.  Our study shows that the 
architecture of the clot proximal to the cell surface depends on cellular procoagulant activity, 
and suggests that understanding how clots are anchored to surrounding cells will explain 
mechanisms that cause some thrombi to be prone to embolism. 
 In summary, we have demonstrated that different cells of the vascular wall regulate 
thrombin generation and clot formation differently, profoundly affecting the structure and 
stability of the fibrin network.  However, independently of cell type, fibrin density is greatest 
proximal to the cell surface compared to distal regions of the clot suggesting, localized 
thrombin generation alters the three-dimensional structure of the clot, 
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Chapter 5 
Summary and Future Direction of Research 
 
5.1  Summary and future direction of research 
 Previous studies have used different conditions to demonstrate that local pH, ionic 
strength, and the concentrations of calcium, fibrinogen, and thrombin present can influence 
clot structure and stability (reviewed in [1, 2]).  However, the concentration of thrombin 
present at the time of gelation likely has the most profound physiologic influence on clotting.  
In vitro assays using a single concentration of thrombin have shown that the thrombin 
concentration determines the structure of the fibrin clot.  Low thrombin concentrations 
produce turbid, porous clots with thick fibrin fibers, and these clots are particularly 
susceptible to fibrinolysis.  In contrast, high thrombin concentrations form clear, tightly-
packed clots with thin fibrin fibers, and these clots are more resistant to fibrinolysis [3, 4].  
These differences in fibrinolytic susceptibility have significant physiologic implications:  
clots resistant to fibrinolysis are prone to thrombosis, whereas clots that are highly 
susceptible to fibrinolysis are prone to premature lysis and bleeding [5]. 
 In vivo, however, thrombin is actively generated on a cell surface, resulting in a 
dynamically changing thrombin concentration.  Therefore, to fully appreciate the role of 
thrombin in clot formation and stability, it is important not to use only a single concentration 
of thrombin, but to examine how in situ thrombin generation influences fibrin clot structure.  
To focus on the role of in situ thrombin generation in clot formation, our lab has developed a 
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cell-based model of hemostasis using tissue factor-bearing cells, platelets, purified 
coagulation proteins, and fibrinogen to examine how thrombin generated on the cell surface 
ultimately affects the structure of the clot [6-8].  The development of this model allows us to 
observe how the absence of certain coagulation proteins affects thrombin generation and the 
subsequent effect on clot structure and stability.  For example, the absence of factors VIII 
and IX in our cell-based system models the bleeding disorder hemophilia [7].  In the absence 
of these factors, the rate of thrombin generation is reduced, resulting in a slower rate of clot 
formation.  Furthermore, clots formed under these conditions are composed of thicker fibers, 
which are highly susceptible to fibrinolysis [7].   
 In Chapter 2 of this dissertation, we used this model of hemophilia to determine whether 
a cell-based therapy involving the combination of rehydrated, lyophilized (RL) platelets (a 
cellular component) and recombinant factor VIIa (rFVIIa, a drug used to treat hemophilia) 
improved thrombin generation and the quality of the fibrin network over rFVIIa alone.  In 
these studies, a clinically relevant dose of rFVIIa (50 nM) improved the rate of thrombin 
generation under hemophilic conditions.  However, the addition of RL platelets and a sub-
clinical dose of rFVIIa (10 nM) improved thrombin generation to the same extent.  
Furthermore, RL platelets combined with 10 nM rFVIIa improved the rate of clot formation 
and the stability of the clot in a fibrinolytic environment to similar levels seen with 50 nM 
rFVIIa, alone.  We extended these findings into a more physiological setting, using platelet-
rich plasma from hemophilic patients.  Interestingly, we found two individuals whose plasma 
responded to RL platelets and rFVIIa treatment over rFVIIa treatment alone, while two 
others responded equally well to rFVIIa or RL platelets with rFVIIa.  These results suggest 
that the quality of the platelet, the cellular component involved in thrombin generation, plays 
 139
a critical role in determining the efficacy of rFVIIa therapy.  In patients with platelets, which 
have a high capacity to support thrombin generation, rFVIIa treatment alone works 
efficiently.  However, in patients with platelets that have a low capacity to support thrombin 
generation, the added cellular component of RL platelets makes rFVIIa therapy effective.  
 The next step in these studies needs to involve in vivo models of hemophilia such as the 
hemophilia B dog and mouse models [9-12].  Use of these animal models will allow us to 
determine if the combination of RL platelets and rFVIIa improves clot stability in vivo.  
Furthermore, these animal models will allow us to examine whether a therapy of RL platelets 
with pre-bound rFVIIa results in more localized thrombin generation, causing a reduction in 
bleeding time or possibly requiring a lower dose of rFVIIa to reach efficacy compared to 
simultaneous infusion of RL platelets and rFVIIa.  In addition to moving into in vivo studies, 
future ex vivo studies should address the process of determining which patients might benefit 
from a combined RL platelet and rFVIIa therapy.  Clinically, some hemophilic patients 
respond to rFVIIa infusion and are classified as responders [13].  On the other hand, a subset 
of patients receiving rFVIIa respond very poorly to rFVIIa treatment and are thus defined as 
non-responders [13].  Based on our results that some patients respond to rFVIIa combined 
with RL platelets and others do not, we have hypothesized that the quality of the endogenous 
platelet population dictates whether an individual responds to rFVIIa therapy.  Future studies 
must examine whether platelets involved in mediating thrombin generation are responsible 
for rFVIIa efficacy or whether the necessary constituent is a soluble component of patient 
plasma.   
 In Chapters 3 and 4 of this dissertation, we began to examine the properties of cells other 
than platelets that may play a role in thrombin generation and clot formation.  We used 
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purified and plasma-derived systems to determine that localized thrombin generation on a 
cell surface, such as fibroblasts, causes a denser network of fibrin proximal to the cell 
surface.  This denser network had functional significance to the structural stability of the clot; 
fibrin proximal to the cell surface took longer to lyse compared to distal regions of the clot.  
 We next examined properties of intravascular and extravascular cells that may influence 
cell-supported thrombin generation.  Intravascular cells supported low levels of thrombin 
generation due to their low expression of TF and their ability to support APC generation.  
Due to the low levels of thrombin generation supported by these cells, the subsequent clots 
were loosely woven and contained thick fibers.  On the other hand, extravascular cells 
supported rapid rates of thrombin generation and clot formation.  These clots were composed 
of a denser network of thinner fibers and were more stable in our tPA lysis assays.  
Interestingly, endothelial cells exposed to inflammatory cytokines supported faster rates of 
thrombin generation and more stable clots compared to unstimulated endothelial cells, 
providing a novel link between inflammation, coagulation, and fibrin clot structure. This 
study also confirmed our previous findings that the fibrin network was denser proximal to the 
cell surface, independent of the rate of thrombin generation [14].   
 These studies offer insight into how different cellular properties modulate the rate of 
thrombin generation and the subsequent effect on clot formation and stability.  This model 
may be useful in future studies to address the idea of vascular-bed specific thrombosis.  Do 
different regions of the endothelium express certain properties such as TFPI, TM, and 
endothelial protein C receptor, which modulate how thrombin is generated on their surface?  
Furthermore, does cellular activation through inflammatory mediators of arterial, venous, or 
microvascular endothelial cells result in the expression of different cellular properties that 
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contribute to thrombin generation in unique ways and promote pathological clot formation?  
These future experiments will help address the hypothesis that different vascular beds have a 
delicate balance of pro-and anti-coagulant properties that when altered results in site specific 
thrombosis. 
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